

NANCY KAY OSTROM, MD, CPI

Private Practice 1986-present
Co-director, Allergy & Asthma Medical Group and Research Center, A P.C.

Associate Clinical Professor, Department of Pediatrics, Division of Allergy and Immunology
University of California, San Diego

CRN Clinical Research Network
President

Certified Physician Investigator,
Academy of Pharmaceutical Physicians and Investigators

5776 Ruffin Rd
San Diego, CA 92123

<u>Research</u>	<u>Clinic</u>
(858) 268-2368 phone	(858) 292-1144 phone
(858) 268-5147 fax	(858) 268-5145 fax
nancyostrom@allergyandasthma.com	

California Medical License Number: G56048

EDUCATION:

University: Hamline University, St. Paul, MN, BA degree (summa cum laude),
Biology, 1972-1976

Medical School: Mayo Medical School, Rochester, MN, MD degree, 1976-1980

Internship: Pediatrics, Mayo Graduate School of Medicine, Rochester, MN, 1980-1983

Residency: Pediatrics, Mayo Graduate School of Medicine, Rochester, MN, 1981-1983
Pediatric Resident Representative (Chief Resident), 1981-1983

Fellowship: Allergy/Immunology, Mayo Graduate School of Medicine,
Rochester, MN, 1983-1985
Visiting Fellow Clinical Immunology/Allergy, University of California,
Los Angeles, May-June, 1984

BOARD CERTIFICATIONS & LICENSURE:

Diplomate, National Board of Medical Examiners, 1981

Diplomate, American Board of Pediatrics, 1984

Diplomate, American Board of Allergy and Immunology, 1987

Medical Licensure: California, 1985 (License Number: G56048)

Certified Clinical Investigator: DIA (CCI) 2004

Certified Physician Investigator (CPI): Academy of Pharmaceutical Physicians and Investigators
(APPI) 2006

HONORS/AWARDS:

Hamline University

Presidential Scholar, 1972-1976

Phi Beta Kappa, 1975

Mayo Graduate School of Medicine

Pediatric Junior Resident Trip Award, 1980

Pediatric Senior Resident Travel Award, 1983

Mayo Foundation Pediatric Award for Academic Achievement 1983

American College of Allergy Travel Award, 1984

American Academy of Allergy and Immunology Travel Award, 1985

San Diego Top Doctors, Allergy & Immunology, San Diego Magazine, 2003, 2008, 2009

San Diego Super Doctors

America's Top Doctors 2001, 2002, 2003, 2004, 2007, 2008, 2009, 2010, 2011, 2012

Best Doctors in America 2007-2008, 2009-2010, 2010-2011, 2011-2012

ACADEMIC APPOINTMENTS:

Curriculum Review Committee, Hamline University, 1975-1976

Freshman Curriculum Committee, Mayo Medical School, 1979

Freshman Student Advisor, Mayo Medical School, 1979

Pediatric Hospital Practice Committee, Mayo Clinic, 1982-1983

Pediatric Education Committee, Mayo Clinic, 1982-1983

Senior Resident Associate, Pediatrics, Mayo Clinic, Rochester, MN, 1983

Pediatric Preceptor, Mayo Medical School, Rochester, MN, 1985

Senior Clinical Fellow in Pediatric Allergy/Immunology, Mayo Clinic, Rochester, MN, 1985

Adjunct Clinical Professor, San Diego State University School of Nursing, 1993

Scripps Clinic Research Foundation, Allergy and Immunology Residency Training Program
Preceptor, 1987 to present

PROFESSIONAL APPOINTMENTS:

Fellow, American Academy of Allergy, Asthma and Immunology

Chair, Physicians/Public Services Council, 2001-2003

Chair, Women's Involvement in the AAAAI, 2001-2003

Chair, Asthma Pharmacotherapeutics Committee, 2005 - 2006

Chair, Public Education Committee, 2006 -2007

Member, Health Education Delivery and Quality (HEDQ) interest section; Quality
Adherence and Outcomes Committee, 2013-present

Fellow American College of Allergy, Asthma and Immunology

Chair, Asthma Committee, 1992 to 1994

Managed Care Liaison Council

Vice Chair, Women's Health Committee

American Thoracic Society

Fellow, American Academy of Pediatrics

California Society of Allergy, Asthma and Clinical Immunology

California Medical Association

San Diego Allergy Society, President, 1997 to 1999

American Lung Association, Scientific Advisory Council, 1998 to 2000

PROFESSIONAL APPOINTMENTS (cont.):

San Diego County Medical Society
Member, Children's Hospital Institutional Review Board, 1995-2006

EDITORIAL BOARDS:

Annals of Allergy, Asthma and Immunology
Journal of Asthma

MEDICAL STAFF:

Rady Children's Hospital and Health Center, San Diego, CA.
Sharp Memorial Hospital, San Diego, CA.
Scripps Mercy Hospital, San Diego, CA.

GRANTS:

1. Exercise Limitation and Surgical Outcome in Patients with Pectus Excavatum, funded by Mayo Foundation Research and Development

PUBLICATIONS:

1. Ostrom NK, O'Connell EJ, Yunginger JW: Mastocytosis syndrome: Case report and pharmacologic control of mediator effects. (abstr) *Ann Allergy* 1984;52:239.
2. Ostrom NK, Swanson MC, Agarwal MK, Yunginger JW: Occupational allergy to honeybee whole body dust in a honey processing plant. (abstr) *J Allergy Clin Immunol* 1985;75:134.
3. Ostrom NK, Swanson MC, Agarwal MK, Yunginger JW: Occupational allergy to honeybee-body dust in a honey processing plant. *J Allergy Clin Immunol* 1986;77:736.
4. Wynn SR, Sachs MI, Keating MU, Ostrom NK, Kadota RP, O'Connell EJ, Smithson WA: Idiopathic hypereosinophilic syndrome in a 5 1/2 month old infant. *J Pediatr* 1987;111:94.
5. Wynn SR, Driscoll DJ, Ostrom NK, et al. Exercise cardiorespiratory function in adolescents with pectus excavatum. Observations before and after operation. *J Thorac Cardiovasc Surg.* 1990 Jan; 99(1):41-7.
6. Jalowayski AA, Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Ostrom NK: Flow-volume curves in young children aided by a hugger pressurized system (HPS). (abstr) *J Allergy Clin Immunol* 1987;79:147.
7. Orgel HA, Meltzer EO, Kemp JP, Ostrom NK, Welch MJ: Comparison of intranasal cromolyn sodium and oral terfenadine for allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1988;81:256.
8. Meltzer E, Kemp J, Orgel A, Ostrom N, Welch M: Intranasal fluticasone propionate for treatment of seasonal allergic rhinitis. (abstr) *N Engl Reg Allergy Proc* 1988;9:387.
9. Orgel HA, kemp JP, Meltzer EO, Ostrom NK, Welch MJ: Severe vocal cord dysfunction in a child with asthma. (abstr) *J Allergy Clin Immunol* 1989;83:176.
10. Welch MJ, Meltzer EO, Orgel HA, Ostrom NK, Kemp JP: Evaluation of self-administered blood theophylline testing in patients on regular theophylline therapy. (abstr) *J Allergy Clin Immunol* 1989;83:180.
11. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Ostrom NK, Gowarty HA, Cocchetto DM: A comparative study of salmeterol, albuterol and placebo via MDI in asthmatic adults. (abstr) *J Allergy Clin Immunol* 1989;83:186.
12. Ostrom NK, Kemp JP, Meltzer EO, Orgel HA, Welch MJ: Use of anterior rhinometry (AR) in assessing clinical response to a new inhaled nasal steroid in children. (abstr) *J Allergy Clin Immunol* 1989;83:278.
13. Meltzer EO, Kemp JP, Orgel HA, Ostrom NK, Welch MJ: Evaluation of two formulations of flunisolide nasal spray in patients with perennial allergic rhinitis. (abstr) *Ann Allergy* 1989;62:239.
14. Welch MJ, Meltzer NK, Ostrom NK, Kemp JP, Orgel HA, Betlach CJ: Pharmacokinetic evaluation of Theo-Dur 450 mg (Theo 450) tablets given BID vs. Theo-Dur 300 mg (Theo 300) TID. (abstr) *Ann Allergy* 1989;62:267.
15. Ostrom NK, Welch MJ, Bronsky EA, Grossman J, Shapiro GG, Tinkelman DG, Garcia JD, Gillen MS: Clinical and rhinomanometric evaluation of triamcinolone acetonide nasal aerosol (TANA) in children with perennial allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1990;85:237.
16. Kemp JP, Meltzer EO, Orgel HA, Ostrom NK, Welch MJ: Evaluation of tolerance during 8 weeks of astemizole or terfenadine therapy in patients with perennial allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1990;85:243.

17. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Ostrom NK: A comparison of the bronchodilator and adverse effects of a liposome-encapsulated metaproterenol (LMS) and metaproterenol sulfate (MS) nebulizer solution in patients with asthma. (abstr) *Ann Allergy* 1990;64:78.
18. Welch MJ, Meltzer EO, Kemp JP, Orgel HA, Ostrom NK, Jalowayski AA: Comparison of two different techniques for obtaining specimens for nasal cytology: Nose-blowing vs. nasal mucosa scraping. (abstr) *J Allergy Clin Immunol* 1991;87:144.
19. Jalowayski AA, Meltzer EO, Ostrom NK: Nasal histamine levels in young children with allergic and non-allergic rhinitis and chronic otitis. (abstr) *J Allergy Clin Immunol* 1991;87:146.
20. Welch MJ, Kemp JP, Meltzer EO, Orgel HA, Ostrom NK: Asthma in the schools. *Immunol Allergy Clin North Am* 1991;11:173-181.
21. Ostrom N, Welch M, Klinger N, Romero L, McCarville S, Harrison L: Comparison of a new once-daily theophylline preparation with theodur (T) given BID. (abstr) *J Allergy Clin Immunol* 1992;89:191.
22. Welch MJ, Ostrom NK, Meltzer EO, Orgel HA: Nonpharmacologic approaches to the management of asthma. In: Tinkelman DG, Falliers CJ, Naspitz CK (eds): Childhood asthma: pathophysiology and treatment. New York, 1993, Marcel Dekker, Inc., pp. 457-95.
23. Kemp JP, Meltzer EO, Welch MJ, Ostrom NK, Orgel HA, Robinson RE: Effectiveness of MDL 26,024GO in suppressing skin reactivity to antigen challenge. (Abstr) *J Allergy Clin Immunol* 1993;91:379.
24. Welch MJ, Kemp JP, Ostrom NK, Orgel HA, Meltzer EO, Romero LT, Klinger N, McCarville S, Harrison LI: A comparative study of a new once-a-day theophylline preparation with Theo-Dur given twice daily. *J of Asthma* 1993;30(3):211-18.
25. Jalowayski AA, Meltzer EO, Orgel HA, Kemp JP, Ostrom NK, Welch MJ, Basch C, Bynum L, Munchi A: Anterior rhinomanometry in allergic rhinitis patients treated with flunisolide, beclomethasone dipropionate or placebo nasal spray. (abstr) *J Allergy Clin Immunol* 1994;93:164.
26. Ostrom N, Welch M, Morris R, Rosen J, Wanderer A, Dockhorn R, Tinkelman D, Vandewalker M, Ziering W: Evaluation of ebastine (Eba), a new non-sedating antihistamine, in children with seasonal allergic rhinitis (SAR). (abstr) *J Allergy Clin Immunol* 1994;93:163.
27. Pearlman DS, Ostrom NK, Bronsky EA, Hanby MS, Bonuccelli CM: Efficacy and safety of Zafirlukast (Accolate®) in pediatric patients with exercise-induced asthma. (abstr) *Ann Allergy Asthma Immunol* 1997;78:113.
28. Ostrom NK: Book Chapter: Treatment of Exercise-Induced Asthma: Beta Agonists. In: Weiler JM (ed.): Allergic and Respiratory Disease in Sports Medicine. New York, 1997, Marcell Dekker, Inc., pp. 141-58.
29. Pearlman DS, Ostrom NK, Bronsky EA, Bonuccelli CM, Hanby LA. The leukotriene D₄-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. *J Pediatr* 1999;134:273-9.
30. Santanello N, DeMuro-Mercon C, Davies G, Ostrom NK, Noonan M, Rooklin A, Knorr B: Validation of a pediatric asthma caregiver diary. *J Allergy Clin Immunol* 2000;106: 861-6.
29. Ostrom NK: Asthma Management: Proper Uses of Pharmacotherapy. *U.S. Pharmacist*, 2001;53-62.
30. Ostrom NK: Scope and Impact of Allergic Rhinitis. New Developments in the Treatment of Pediatric Allergic Rhinitis, New Jersey, 2002 Professional Postgraduate Services.

31. Ostrom NK (ed): New Developments in the Treatment of Pediatric Allergic Rhinitis. New Jersey, 2002, Professional Postgraduate Services.
32. Ostrom NK, Cruz-Rivera M: Prescription patterns among obstetrics and gynecology physicians (OB/GYNS) for pregnant and non-pregnant asthmatic patients. *Ann Allergy Asthma Immunol* 2003;90:144.
33. Welch MJ, Gallet C, Ostrom NK, Meltzer EO. Evaluation of efficacy and patient preference of albuterol delivered via the PocketChamber (PC) versus the Aerochamber (AC Plus) in patients with asthma. (abstr) *J Allergy Clin Immunol* 2003;111:S145
34. Ostrom NK, Park P, Cruz-Rivera M. Allergist and pulmonologist prescribing of inhaled corticosteroids for pregnant and nonpregnant women with asthma. (abstr) *J Allergy Clin Immunol* 2003;111:S220.
35. Ostrom NK. Tolerability of Short-Term, High-Dose Formoterol in Healthy Volunteers and Patients with Asthma. *Clinical Therapeutics* 2003;25(11):2635-46.
36. Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, Crim C. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. *J Pediatr* 2005; 147: 213-20.
37. Ostrom NK, Meltzer EO, Welch MJ. At what age can a child swallow a pill? (abstr) *J Allergy Clin Immunol* 2005; 115: S42.
38. Ostrom NK. Outpatient Pharmacotherapy for Pediatric Asthma. *J Pediatr* 2006;148:108-14.
39. Ostrom NK. Women with asthma: a review of potential variables and preferred medical management. *Ann Allergy Asthma Immunol* 2006;96: 655-665.
40. Ostrom NK, Goergen BS. Asthma management in women. *J Nurse Pract* 2006; 2: 450-459.
41. Meltzer EO, Welch MJ, Ostrom NK. Pill Swallowing Ability and training in Children 6 to 11 Years of Age. *Clinical Pediatrics* 2006;45:725-733.
42. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. *J Allergy Clin Immunol* 2007; 119: 817-25.
43. Sorkness C, Liu A, Blaiss M, Mahr T, Chipps B, Ostrom N, et al. Longitudinal validation of the childhood asthma control test. *Am J Respir Crit Care Med* 2007; 175: A782.
44. Nathan RA, Kanter L, Ostrom NK. Ciclesonide improves health-related quality of life in adults and adolescents with mild-to-moderate persistent asthma. *Allergy Asthma Proc* 2008;29:521-7.
45. Koenig SM, Ostrom N, Pearlman D, Waitkus-Edwards K, Yancey S, Prillaman BA, Dorinsky P. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down". *J Asthma* 2008;45:681-7.
46. Liu AH, Zeiger RS, Sorkness CA, Ostrom NK, Chipps BE, Rosa K, Watson ME, Kaplan MS, Meurer JR, Mahr TA, Blaiss MS, Piauult-Louis E, McDonald J. The Childhood Asthma Control Test: retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthma. *J Allergy Clin Immunol* 2010;126:267-73.
47. Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, Prillaman BA, Ortega HG. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. *Allergy Asthma Proc* 2010; 31: 68-75.
48. Stoloff SW, Colice GL, Hayden ML, Craig TJ, Ostrom NK, Eid NS, Parsons JP. Exercise-induced bronchospasm: implications for patients with or without asthma in primary care practice. *Int J Gen Med*. 2011;4:779-82. Epub 2011 Nov 18.
49. Ostrom NK, Eid NS, Craig TJ, Colice GL, Hayden ML, Parsons JP, Stoloff SW. Exercise-induced bronchospasm in children with asthma in the United States: Results from the Exercise-Induced Bronchospasm Landmark Survey. *Allergy Asthma Proc* 2011;32:425-430.

50. Parsons JP, Craig TJ, Stoloff SQ, Hayden ML, Ostrom NK, Eid NS, Colice GL. Impact of exercise-related respiratory symptoms in adults with asthma: Exercise-Induced Bronchospasm Landmark National Survey. *Allergy Asthma Proc* 2011;32:431-437.
51. Colice GL Ostrom NK, Geller DE, Anolik R, Blaiss M, Marcus P, Schwartz J, Nathan RA. The CHOICE survey: high rates of persistent and uncontrolled asthma in the United States. *Ann Allergy Asthma Immunol* 2012; 108: 157-162.
52. Ostrom NK, Parsons JP, Eid NS, Craig TJ, Stoloff S, Hayden ML, Colice GL. Exercise-induced bronchospasm, asthma control, and obesity. *Allergy Asthma Proc*; 2013 Jul-Aug;34(4):342-8.
53. Ostrom NK: The history and progression of treatments for allergic rhinitis. *Allergy Asthma Proc* 2014: 35 (3); S3-S10.
54. Hoyt FC, Meltzer EO, Ostrom NK, et al.: Recommendations for the pharmacologic management of allergic rhinitis. *Allergy Asthma Proc* 2014: 35 (3): S20-S27

RESEARCH:

1. Uncoupling of oxidative phosphorylation in the overwintering honeybee, *Apis mellifera*.
2. Development of erythrocyte cell culture.
3. Transient inhibition of protein synthesis: A model for Reyes syndrome.
4. Cardiopulmonary function during dynamic exercise testing in patients with pectus excavatum.
5. Urticaria pigmentosa and mastocytosis syndrome.
6. Inhalant occupational allergens: Collection, identification and clinical significance.
7. Exercise-induced anaphylaxis.
8. Three month study of the comparative efficacy and safety of procaterol and isoproterenol aerosol inhalation in pediatric outpatients with reversible bronchial airway obstruction.
9. The effect of one week of oral AHR-11325 (10, 25 and 50 mg), brompheniramine (4 mg) or placebo in allergic rhinitis patients.
10. A study of the efficacy and safety of loratadine in patients 6-12 years of age with seasonal allergic rhinitis.
11. A comparative study of triamcinolone acetonide and flunisolide nasal solution sprays in subjects with seasonal allergic rhinitis.
12. A one-month study of the safety and efficacy of procaterol syrup in 2-6 year old children with reversible bronchial airway obstruction.
13. A tolerance study of terfenadine-pseudoephedrine combination tablets in comparison to pseudoephedrine tablets in patients with seasonal or perennial allergic rhinitis.
14. A placebo-controlled comparison of azelastine, controlled release theophylline and combined azelastine-theophylline therapy in the management of patients with nonsteroid dependent bronchial asthma.
15. An open, long-term study of the safety and efficacy of cetirizine in chronic allergic diseases.
16. A crossover comparison of the duration of effectiveness of aerosol procaterol and albuterol in the prevention of exercise-induced asthma.
17. The role of ketotifen as an additive therapy in the prophylactic treatment of moderate asthma.
18. A controlled study of triamcinolone acetonide nasal aerosol and placebo in patients with perennial rhinitis.
19. The effects of rocastine, chlorpheniramine (4 mg) or placebo in adults with symptomatic seasonal allergic rhinitis.
20. A comparison of the therapies for children with chronic asthma of inhaled albuterol plus BID oral theophylline to inhaled albuterol plus QID inhaled beclomethasone to inhaled albuterol plus BID oral theophylline and QID inhaled beclomethasone.
21. A parallel study of the effectiveness and safety of azelastine, clemastine and placebo for the management of perennial allergic rhinitis.
22. A comparison of terfenadine 60 mg BID, chlorpheniramine, 4 mg TID and placebo in patients in patients with perennial rhinitis.
23. An open-label, long-term study of triamcinolone acetonide nasal aerosol in patients with perennial rhinitis.
24. LY171883 vs. placebo in theophylline-controlled asthmatics.
25. A comparison of the safety and efficacy of cromolyn sodium 4% nasal solution and terfenadine tablets in the treatment of allergic rhinitis.
26. A safety evaluation of metaproterenol sulfate liposome inhalant concentrate.
27. A 12-week, placebo-controlled trial of oxitropium bromide for asthma.

28. A double-blind study of triamcinolone acetonide nasal aerosol and placebo in patients with perennial rhinitis.
29. An open-label, one month study of procaterol syrup in young children with reversible bronchial airway obstruction.
30. Comparison of efficacy and side effects of enprofylline, theophylline and placebo in patients with mild to moderate asthma.
31. The clinical evaluation of the safety and efficacy of astemizole as compared to terfenadine in the treatment of perennial allergic rhinitis.
32. Comparison of cetirizine with chlorpheniramine in the treatment of seasonal allergic rhinitis in children, 6-11 years of age.
33. A long-term, safety study of triamcinolone acetonide nasal aerosol in patients with perennial rhinitis.
34. Dose-ranging study of the comparative efficacy and safety of tazifylline and placebo in patients with allergic seasonal rhinitis.
35. A pharmacokinetic and pharmacodynamic study of metaproterenol in asthmatic children.
36. A study evaluating the efficacy and safety of daily administration of 100, 400 and 1600 mcg aqueous fluticasone propionate vs. placebo in patients with allergic seasonal rhinitis.
37. A placebo-controlled comparison of the effectiveness and safety of azelastine and oral albuterol sulfate in the management of symptomatic bronchial asthma.
38. A parallel study of intranasal ipratropium bromide nasal spray versus placebo in nonallergic perennial rhinitis.
39. Placebo-controlled evaluation of the protective activity of azelastine in methacholine-induced bronchoprovocation.
40. An evaluation of two formulations of flunisolide nasal spray in patients with perennial allergic rhinitis.
41. A three-month study of the efficacy and safety of procaterol and metaproterenol in pediatric patients with asthma.
42. Multiple dose pharmacokinetic evaluation of Theo-Dur 450 mg tablets in adult asthmatic patients.
43. A study of triamcinolone acetonide nasal aerosol and placebo in pediatric patients with perennial allergic rhinitis.
44. A safety and efficacy evaluation of several single doses of salmeterol hydroxynaphthoate in asthmatic patients.
45. A comparison of terfenadine 60 mg BID and 120 mg BID in the treatment of patients with seasonal allergic rhinitis who are less than optimal responders to terfenadine 60 mg BID.
46. A study comparing two single doses of BMY 26517-31 to placebo in patients with exercise-induced bronchospasm.
47. A dose-ranging study of twice-daily intranasal administration of aqueous fluticasone propionate in adult patients with seasonal allergic rhinitis.
48. A single dose, duration of action comparative study of pirbuterol, albuterol and placebo aerosols.
49. A comparison of azelastine and clemastine fumarate to placebo in the management of perennial allergic rhinitis.
50. An albuterol-controlled, 12-week study of procaterol TID in outpatients with reversible bronchial airway obstruction.
51. A controlled study of HEPP (IgE pentapeptide) nasal solution as treatment of seasonal allergic rhinitis.
52. A comparison of the efficacy and duration of action of two different albuterol delivery systems: the DiskhalerTM vs. the Rotahaler^R.

53. A placebo controlled park study of Rynatan tablets in subjects with allergic rhinitis.
54. A placebo controlled park study of Rynatan suspension in subjects with allergic rhinitis.
55. A parallel comparison of intranasal atrovent nasal spray versus placebo in nonallergic perennial rhinitis.
56. Placebo controlled comparison of azelastine and oral albuterol sulfate in the management of symptomatic bronchial asthma.
57. A placebo-controlled study of once- versus twice-daily intranasal fluticasone propionate for patients with seasonal allergic rhinitis.
58. A tablet comparison study of Theo-Dur 300 mg TID and 450 mg BID.
59. Study of adrenal function in adult asthmatics during chronic treatment with 800, 1200 and 1600 mcg aerosolized triamcinolone acetonide.
60. A clinical trial of four dosage regimens of salmeterol hydroxynaphthoate versus placebo in patients with chronic reversible obstructive airways disease.
61. Intranasal ipratropium bromide nasal spray versus placebo in allergic perennial rhinitis.
62. An open-label clinical evaluation of Uni-Dur^R, a twenty-four hour theophylline sustained release tablet.
63. BMY-26517/placebo group study of patients with chronic asthma requiring bronchodilator therapy.
64. Pentigetide for injection - an open label safety study.
65. A comparison of oral theophylline and aerosol beclomethasone dipropionate therapy of asthma.
66. A placebo-controlled assessment of flunisolide nasal spray as an adjunct in the treatment of sinusitis.
67. A placebo-controlled trial to evaluate once-daily versus twice-daily intranasal administration of aqueous fluticasone propionate versus beclomethasone dipropionate in patients with perennial allergic rhinitis.
68. A parallel group study of the safety, efficacy and duration-of-action of azelastine, albuterol sulfate repetabs and placebo tablets in subjects with chronic asthma.
69. The clinical evaluation of the safety and efficacy of astemizole suspension in the treatment of seasonal allergic rhinitis in children.
70. A placebo-controlled study to investigate RG-3988 aerosol in theophylline-dependent asthmatics.
71. A comparative study of the efficacy and safety of nedocromil sodium nebulizer solution vs. placebo in the management of patients with reversible airway obstruction.
72. A comparison of the effectiveness and safety of azelastine, chlorpheniramine maleate, and placebo tablets in the management of patients with seasonal allergic rhinitis.
73. A placebo-controlled study of aqueous fluticasone propionate given once-versus twice-daily versus aqueous beclomethasone dipropionate versus placebo in adult and adolescent patients with seasonal allergic rhinitis.
74. A comparison of inhaled ipratropium bromide placebo when each is added to inhaled albuterol for maintenance treatment of patients with asthma.
75. A study to evaluate the safety and efficacy of terfenadine suspension in the prophylactic treatment of children ages 6 through 12 with allergic asthma who experience seasonal exacerbations.
76. A stratified, group-sequential study to compare the efficacy of rising doses of MK-571 to placebo in patients with chronic stable asthma.
77. A study of cetirizine in the treatment of seasonal allergic rhinitis in children 6 to 11 years of age.
78. An evaluation of the therapeutic effect of oral ICI 204,219 on bronchial asthma.

79. Loratadine versus pseudoephedrine versus the combination versus placebo as treatment for seasonal allergic rhinitis .
80. A study of aqueous fluticasone propionate given once daily versus placebo in pediatric patients with seasonal allergic rhinitis.
81. A dose-ranging and duration-of-action trial of azelastine nasal spray (0.1%) in subjects with seasonal allergic rhinitis.
82. A comparative study of nedocromil sodium nebulizer solution versus placebo in children (6-12 years of age) with asthma induced by symptomatic respiratory infections.
83. A study of the comparative efficacy and safety of procaterol and albuterol aerosol in pediatric patients with reversible airway obstruction.
84. A clinical and electrocardiographic study of potential pharmacodynamic interactions of salmeterol hydroxynaphthoate and theophylline in patients with chronic reversible obstructive airways disease.
85. Open-label comparative safety and efficacy study of two theophylline formulations: TCR1 and Theo-Dur^R.
86. Auranifin versus placebo in the treatment of steroid-dependent asthma.
87. Crossover, dose-ranging study of inhaled ipratropium bromide and placebo in children with chronic asthma.
88. Evaluation of the applicability and sensitivity of the medical outcomes study short form 36 plus disease-specific questions to patients with asthma or allergic rhinitis.
89. A double-blind, randomized, parallel study comparing the safety and efficacy of terfenadine 60 mg BID, astemizole 10 mg QD and placebo in the treatment of seasonal allergic rhinitis in an "in the park" setting.
90. Comparison of duration of action and side effects of metaproterenol sulfate liposome (metasome) and alupent in asthmatics.
91. Evaluation of flunisolide nasal spray as an adjunct in the treatment of sinusitis.
92. A clinical trial of twelve-week courses of salmeterol hydroxynaphthoate versus albuterol versus placebo in patients with chronic reversible obstructive airways disease.
93. A pilot study of terfenadine 60 mg bid and placebo in the treatment of patients with mild to moderate atopic asthma who demonstrate a positive challenge to methacholine and exercise.
94. A trial to assess the safety and tolerability of azelastine nasal spray (0.1%) in subjects with perennial allergic rhinitis.
95. Histamine levels in nasal mucosa scraping of normal children and those with rhinitis and chronic otitis media.
96. A clinical study comparing the efficacy of intranasal triamcinolone acetonide spray and bioequivalent doses of intramuscular triamcinolone acetonide in patients with seasonal rhinitis.
97. A double-blind study to compare the efficacy of three doses of MK-0679 to placebo in patients with chronic stable asthma.
98. Auranifin vs. placebo in the treatment of steroid-dependent asthma.
99. An efficacy trial of comparable plasma concentrations of triamcinolone acetonide given by inhalation (Azmecort) and intramuscular injection (Kenalog-40) in the management of moderate asthmatics.
100. Beclomethasone dipropionate vs. cromolyn vs. placebo, effects in children with seasonal allergic rhinitis.
101. A parallel group comparison of the efficacy and safety of fluticasone propionate aqueous nasal spray 200 mcg qd versus terfenadine 60 mg bid versus placebo in patients with seasonal allergic rhinitis.

102. A double-blind ascending single-dose study of formoterol suspension aerosol vs. placebo in normal volunteers.
103. Pemirolast/placebo double-blind study of patients with a history of chronic, stable, reversible asthma requiring bronchodilator therapy.
104. Double-blind crossover evaluation of repirinast (Bay u 2372) compared to placebo in attenuation of antigen induced bronchospasm.
105. Efficacy of SCH 37370 in the treatment of mild to moderate asthma.
106. A comparative study of the efficacy and safety of temafloxacin 600 mg bid and ceclor 500 mg Q8H in the treatment of patients with bacterial infection of the lower respiratory tract.
107. A placebo-controlled, double-blind, single-dose study of the effect of RG 12525 on pulmonary function in asthmatics.
108. Liposomal albuterol sulfate aerosol. Escalating dose tolerance safety and efficacy trial.
109. A placebo-controlled study of the efficacy and safety of aqueous fluticasone propionate given twice daily versus placebo for four weeks in patients with perennial non-allergic rhinitis.
110. A cohort epidemiologic study to determine the effect of one year of triamcinolone acetonide on alternate day prednisone or alternate day prednisone plus inhalation or non-steroidal anti-asthmatic therapy on growth patterns of asthmatic children.
111. Bioavailability and pharmacokinetic study of two formulations of flunisolide nasal spray in seasonal allergic rhinitis patients.
112. Inhaled fluticasone propionate vs. theophylline vs. placebo in adolescent and adult patients with mild to moderate asthma.
113. A comparative study of the safety and efficacy of cetirizine or placebo in patients with seasonal allergic rhinitis and asthma.
114. A study to determine the efficacy and safety of three different doses of budesonide delivered by the Turbuhaler to pediatric patients with glucocorticosteroid treated asthma.
115. A study of a single dose of 50 mcg salmeterol hydroxynaphthoate aerosol vs. 180 mcg albuterol aerosol vs. placebo in adolescents and adults with exercise induced bronchospasm.
116. Theophylline sprinkle extended release capsules, dose titration for 6-12 year olds.
117. A comparative trial of two doses of inhaled fluticasone propionate vs. placebo in patients aged 4 to 11 years with mild to moderate chronic asthma.
118. A tolerance study of aqueous film-coated 120 mg terfenadine tablets and placebo tablets administered QD in patients with seasonal or perennial allergic rhinitis.
119. A randomized placebo-controlled comparative study of the efficacy and safety of nedocromil sodium 0.5% nebulizer solution TID in the treatment of children 2-4 years of age with bronchial asthma.
120. A double-blind trial to examine the use of a rescue medication during 6 weeks of astemizole or terfenadine in patients with seasonal allergic rhinitis.
121. A placebo-controlled study of the efficacy and safety of two doses of budesonide delivered by the Turbuhaler to patients with chronic asthma not well controlled on non-steroid therapy.
122. Dose-ranging: six weeks' therapy with oral ICI 204,219 in bronchial asthma.
123. A comparison of long-term prophylaxis with cefuroxime axetil versus placebo in preventing an acute episode of sinusitis in patients with a history of recurrent sinusitis.
124. A comparison of long-term maintenance therapy with cefuroxime axetil versus placebo after treatment of an episode of sinusitis in patients with a history of recurrent sinusitis.
125. Clinical study to evaluate the Biotrack 516 system for therapeutic monitoring of theophylline.

126. Clinical acceptability evaluation of bitolterol inhalation solution 0.2%.
127. A comparison of the effects of astemizole/pseudoephedrine, terfenadine/pseudoephedrine and placebo on sleep and nasal congestion in subjects with seasonal allergic rhinitis.
128. A study to compare the effects of high and low oral doses of ICI 204,219 with placebo given over 6 weeks to patients with asthma.
129. A double-blind comparison of ebastine and placebo in adult patients with seasonal allergic rhinitis.
130. An open-label, long term safety study of ebastine in patients with seasonal allergic rhinitis.
131. MK-0591 Multicenter dose ranging study in patients with moderate asthma.
132. A comparison of budesonide dry powder and placebo in the treatment of children with perennial allergic rhinitis.
133. A placebo-controlled pilot study of the efficacy and safety of single intravenous doses of interleukin-1 receptor antagonist in patients with bronchial asthma.
134. A double-blind comparison of ebastine and placebo in children with seasonal allergic rhinitis.
135. Placebo-controlled comparison of Flunisolide and Beclomethasone Dipropionate in allergic rhinitis.
136. Single intravenous dose efficacy study of MDL 26,024GO in skin reactivity to prick allergen challenge in atopic individuals.
137. A study of the effectiveness of pirbuterol acetate delivered by an Autohaler™ inhalation device vs. pirbuterol acetate delivered by a conventional "press and breathe" metered dose inhaler.
138. A safety/efficacy study of double-strength beclomethasone dipropionate, two inhalations per nostril once daily vs. beclomethasone dipropionate twice daily vs. high dose beclomethasone dipropionate once daily vs. placebo.
139. Multicenter, randomized, double-blind, placebo-controlled, parallel group study comparing the safety and efficacy of five doses of Ro 24-5913 in the treatment of mild to moderate asthma.
140. Double-blind, placebo-controlled, evaluation of azelastine nasal spray (0.1%) in the management of subjects with seasonal allergic rhinitis inadequately controlled by azelastine 0.5mg tablets.
141. A randomized, double-blind, comparative clinical trial of 12-week courses of salmeterol xinafoate rotadisk versus albuterol versus placebo in adolescent and adult patients with chronic reversible obstructive airways disease.
142. Acute pilot probe study of the flurbiprofen nasal spray to nasal allergen challenge in patients with allergic rhinitis.
143. Validation of quality of life questionnaire in patients with asthma using beclomethasone dipropionate.
144. A double-blind, placebo-controlled efficacy study of daily inhaled doses of 200, 400, 800 and 1600mcg triamcinolone acetonide (BID dosing) in moderate asthma.
145. A placebo-controlled trial of Accolate (ICI 204,219) in mild to moderate asthmatic patients needing chronic treatment: 13 weeks efficacy and up to a one year open label safety extension.
146. Phase II safety and efficacy study of Abbott - 73001 in patients with moderate asthma.
147. Placebo-controlled evaluation of the adjunctive therapy of azelastine nasal spray to terfenadine tablets in the management of seasonal allergic rhinitis.
148. A comparative trial assessing the long term safety of inhaled fluticasone propionate rotadisks via diskhaler 50mcg BID and 100mcg BID vs. placebo in patients aged 4 to 11 years with mild to moderate asthma.

149. A study comparing the efficacy and safety of Ro 24-5913 given twice daily with that of placebo for 4 weeks in the treatment of seasonal allergic rhinitis.
150. A double-blind, placebo-controlled study of the safety and efficacy of iodinated glycerol as adjunctive therapy in the treatment of subjects with chronic reversible obstructive airway disease.
151. A study of the safety and efficacy of levocabastine nasal spray twice a day or four times a day in the treatment of seasonal allergic rhinitis.
152. A parallel group study of the safety and inhaled corticosteroid-sparing effect of azelastine in inhaled corticosteroid-dependent asthmatics.
153. A parallel group comparison of ebastine 10mg and 20mg versus placebo in patients with seasonal allergic rhinitis.
154. A 12-week study of HFA-134a salbutamol sulfate, HFA-134a salbutamol sulfate placebo formulation and the standard CFC 11/12 formulation of Ventolin in patients with reversible obstructive airways disease.
155. A double-blind, placebo-controlled, parallel group comparison of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate aqueous nasal spray in patients with seasonal allergic rhinitis.
156. A Phase III study of the effects of Zileuton, 400 mg QID and 600 mg QID compared to beclomethasone in moderate asthma.
157. A safety and efficacy study of loratadine zydys versus loratadine tablet in the treatment of patients with seasonal allergic rhinitis.
158. A multicenter, double-blind comparison of AccolateTM (ICI 204,219) with cromolyn sodium (INTAL, Fisons) in mild to moderate asthmatic patients.
159. A 2-day, placebo- and beclomethasone aqueous nasal spray-controlled study of the safety and efficacy of Azelastine HCl nasal solution) in the management of seasonal allergic rhinitis.
160. A single-blind, placebo-controlled, single-dose pilot study of the bronchodilator response to albuterol dry powder inhaler and metered dose inhaler in asthmatics.
161. An efficacy and safety study of mometasone furoate in perennial rhinitis.
162. A randomized trial to assess the topical versus systemic efficacy of fluticasone propionate rotadisks via diskhaler 500mcg BID, 100mcg BID, fluticasone propionate tablets 20mg QD, and placebo in adult patients with moderate asthma.
163. A comparison of ipratropium bromide nasal spray 0.03% (42 mcg/nostril) versus placebo administered twice a day in pediatric patients with allergic or nonallergic perennial rhinitis with an optional 6-month treatment comparison of ipratropium nasal spray 0.03% (42 mcg/nostril) versus beclomethasone dipropionate aqueous nasal spray (84 mcg/nostril).
164. A placebo-controlled study of the efficacy and safety of four weeks treatment with oral Pfizer CP-80,633 in adult patients with chronic, mild to moderate asthma.
165. A parallel-group park study to compare the onset of action of fluticasone propionate aqueous nasal spray QD versus beclomethasone dipropionate aqueous nasal spray BID for seasonal allergic rhinitis.
166. A study to compare the efficacy and safety of oral doses of Zeneca D2138 with placebo in subjects with bronchial asthma.
167. A long term study of the effects of intranasal beclomethasone dipropionate aqueous nasal spray on the growth and HPA axis function of children.
168. A study to determine the minimum effective dose of levocabastine nasal spray in the treatment of seasonal allergic rhinitis.
169. Nasal cytology - A multicenter study comparing the stained findings in smears of blown nasal secretions and epithelial scrapings.

170. A trial to assess the long term safety of fluticasone propionate Rotadisk^R via Diskhaler^R versus placebo in adult patients with moderate asthma.
171. A 12-month, open-label, follow-up of HFA-134a Salbutamol Sulfate.
172. A pilot study to evaluate the efficacy, tolerability and safety of two doses of HOE 140 (Icatabant) in comparison to placebo in the treatment of chronic bronchial asthma.
173. Efficacy of Claritin^R versus Seldane^R versus placebo upon awakening in seasonal allergic rhinitis.
174. Comparative trial of salmeterol xinafoate rotadisk versus placebo in patients aged 4-11 years with reversible obstructive airways disease.
175. A study comparing duration of action and safety and efficacy of four dosage strengths of MDL 16,455A in the treatment of spring allergies.
176. An evaluation of quality of life and health economic measures in patients receiving MDL 16,455A in the treatment of spring allergies.
177. A crossover study comparing the effects of three oral doses of MK-0476 to placebo on exercise-induced bronchoconstriction 20 to 24 hours after dosing in asthmatics.
178. Attention and cognitive performance in children ages 6-10 years: a placebo-controlled pilot crossover study of the effects of first and second generation antihistamines in children with allergic rhinitis.
179. A placebo-controlled trial of the safety and efficacy of oral Bay x 1005 (100 mg BID vs. 250 mg BID vs. 500 mg BID vs. placebo for 6 weeks) in patients with asthma.
180. Long term safety of mometasone furoate in perennial rhinitis.
181. A trial of the effects of twelve-month courses of salmeterol xinafoate rotadisk versus placebo on methacholine-induced bronchial hyperresponsiveness in patients with chronic asthma.
182. Evaluation of undiluted albuterol inhalation solution in the treatment of acute asthma.
183. A trial of ATROVENT^R nasal spray 0.03% (42 mcg/nostril) alone, antihistamine alone, and the combination of ATROVENT^R nasal spray with an antihistamine in patients with seasonal allergic rhinitis.
184. A 12-month, open-label, safety and efficacy study of HFA-134a salbutamol sulfate and Ventolin in subjects with reversible obstructive airway disease.
185. A long term safety study of fluticasone propionate inhalation aerosol 100 mcg BID and 500 mcg BID versus placebo BID in adults with moderate asthma.
186. A 2-day, outdoor study of the safety and efficacy of cetirizine vs. loratadine and placebo in the treatment of seasonal allergic rhinitis.
187. Dose-ranging effect of Abbott-73001 on bronchial hyperresponsiveness to methacholine in patients with moderate asthma.
188. A placebo-controlled dose response study of Formoterol Turbuhaler 6, 12 and 24 ug administered twice daily in patients with asthma.
189. A long term safety study of mometasone furoate vs. triamcinolone acetonide in perennial rhinitis.
190. An evaluation of the safety, efficacy, and effect on asthma quality of life (AQL) of salmeterol in subjects receiving inhaled corticosteroids.
191. Comparison of 400 mcg HFA-134a beclomethasone dipropionate, 800 mcg CFC-11/12 beclomethasone dipropionate and placebo in subjects with asthma.
192. A dose ranging safety and toleration study of intranasal chlorpheniramine maleate solution in normal subjects.
193. Study of three dose levels of budesonide nebulizing suspension and placebo in asthmatic children aged eight years and younger.

194. A double-blind, crossover study in exercise-induced bronchospasm to compare the safety and efficacy of cromolyn sodium inhalation-isotonic to cromolyn sodium inhalation-hypotonic using placebo control.
195. A study comparing the clinical effect of MK-0476 to placebo in patients with chronic asthma.
196. A comparison of four doses of Rhinocort^R aqua pump spray (Budesonide) and placebo in the treatment of adults and children with perennial allergic rhinitis.
197. A long-term surveillance study of Zileuton plus usual care versus usual care in patients with asthma.
198. A study of the prevalence of human rhinovirus in pediatric asthma patients with upper respiratory illness.
199. Safety and efficacy of mometasone furoate nasal spray vs. placebo in the treatment of elderly patients with perennial rhinitis.
200. Establishing the clinically important aeroallergens (pollens & mold spores) in California for skin testing the patient with respiratory allergy.
201. A placebo-controlled, parallel group comparison of the safety and efficacy of oral twice daily administration of SB 205312 with inhaled Vanceril in patients with mild to moderate asthma.
202. A randomized, double-blind, placebo-controlled, parallel-group evaluation of the safety and efficacy of cromolyn sodium inhalation solution in an isotonic formulation in pediatrics.
203. A multicenter placebo-controlled dose ranging study to assess and compare the activity of an oral administration of SR 27417A once a day during 12 weeks - in moderate asthmatic patients.
204. A placebo-controlled, parallel group, dose rising study to explore the safety, tolerability and preliminary pharmacokinetics of SB 205312 when given twice daily for a period of 7 days to pediatric patients (8-11 years) with mild to moderate asthma.
205. A six month safety/tolerance study of 120 mg MDL 16,455A BID and placebo BID in normal healthy subjects.
206. An efficacy study of RP 73401 DPI administered to moderate asthmatics.
207. A randomized open-label comparison of budesonide aqua pump spray, versus cromolyn sodium in the treatment of children with perennial allergic rhinitis.
208. A randomized open-label comparison of budesonide aqua pump spray, versus beclomethasone dipropionate in the treatment of adults with perennial allergic rhinitis.
209. Safety and efficacy of AA-2414 (ABT-001) in patients with moderate asthma.
210. A randomized, placebo-controlled study to determine the efficacy, maintenance effect, and safety of 200 ug and 400 ug Pulmicort^R Turbuhaler^R given once daily to adults with mild to moderate asthma.
211. A comparison of a daily dose of 100 mcg and 200 mcg of HFA-134a beclomethasone dipropionate with placebo in subjects with mild to moderate reversible obstructive airways disease.
212. An open, long-term study of the safety, tolerability, and efficacy of oral SB 205312 in patients with bronchial asthma.
213. Clinical use study comparing Nasalcrom^R Nasal Solution 4% to placebo nasal solution in the treatment of the symptoms associated with seasonal allergic rhinitis.
214. 4-week safety and efficacy study of HFA-134a salbutamol sulfate versus ventolin in children with reversible obstructive airway disease.
215. A 2-day, outdoor, double-blind, parallel multicenter study of the safety and efficacy of cetirizine vs. loratadine and placebo in the treatment of seasonal allergic rhinitis.

216. A stratified trial assessing the efficacy and safety of fluticasone propionate via the multi-dose powder inhaler, 50mcg bid, 100mcg qd, and placebo in subjects aged 4 to 11 years with chronic asthma.
217. A stratified, comparative trial of inhaled fluticasone propionate via the multi-dose powder inhaler 100mcg QD, 200mcg QD, 500mcg QD, and placebo in adolescent and adult subjects with chronic asthma.
218. A 2-week, placebo-controlled study to assess the safety and efficacy of UK-112,214 (160 and 320 mg BID) in the treatment of adults with seasonal allergic rhinitis.
219. A single-dose, four-way crossover comparison of salmeterol 50mcg and 100mcg via the DiskusTM salmeterol 50mcg via the metered-dose inhaler and placebo for the prevention of exercise-induced bronchospasm in adolescent and adult subjects with asthma.
220. Safety and efficacy study of loratadine zydis vs. loratadine tablets vs. placebo in the treatment of patients with seasonal allergic rhinitis.
221. A placebo-controlled, dose ranging study of Azmacort^R HFA-134a oral inhaler compared to Azmacort^R oral inhaler in the treatment of asthma.
222. A safety study of levocabastine nasal spray used continuously for six months.
223. A placebo-controlled study to investigate the effects of twelve weeks of MK-0476 therapy on exercise and methacholine-induced bronchoconstriction in asthmatics.
224. A placebo-controlled, clinical study of the safety and efficacy of ALLERVAX^R CAT using a cat exposure room challenge model.
225. A placebo-controlled evaluation of the effect of salmeterol on methacholine-induced bronchial hyperresponsiveness over twenty-four weeks in adolescent and adult subjects with asthma.
226. Safety and efficacy of Claritin-D in lessening the exacerbation of asthma associated with seasonal allergic rhinitis.
Pr. No. P95-090
227. A trial of Zafirlukast (AccolateTM) in mild-to-moderate asthmatic subjects requiring first chronic therapy: 13 weeks efficacy and up to 52 weeks open-label safety extension.
Pr. No. 9188IL/0086:0040
228. A parallel group study to evaluate the safety and efficacy of clemastine 0.5mg qid vs. clemastine 1.0 mg bid vs. placebo for allergy symptom relief.
Pr. No. HSC-305
229. A crossover study to evaluate the effects of chewable MK-0476 on exercise-induced bronchoconstriction in 6- to 14-year-old children (Tanner Stages I to V) with mild to moderate asthma.
Pr. No. 042-02
230. A study to investigate the efficacy and safety of GG167 administered twice or four times a day for the treatment of influenza A and B viral infections.
Pr. No. NAIA2008
231. A study to investigate the efficacy and safety of GG167 in the prevention and/or progression of influenza A and B viral infections.
Pr. No. NAIA2009
232. A dose ranging study of mometasone furoate pure dry powder in the treatment of asthma.
Pr. No. C94-127
233. A comparison of the safety and efficacy of pranlukast (SB 205312), 150 and 300 mg BID, with Claritin^R 10 mg UID in patients with seasonal allergic rhinitis.
Pr. No. 205312/048

234. An open-label, four-week extension study to explore safety and efficacy of pranlukast (SB 205312), 300 mg BID, in patients with coexisting seasonal and perennial allergic rhinitis.
Pr. No. 205312/085
235. A single-dose, trial to assess the antagonism of oral Zafirlukast (Accolate™) on exercise-induced bronchoconstriction in pediatric subjects with exercise-induced asthma.
Pr. No. 9188IL/0075
236. A study of the efficacy and safety of fluticasone propionate aqueous nasal spray versus placebo followed by a one year open-label safety extension in subjects with perennial nonallergic rhinitis.
Pr. No. FLTA3010
237. A six month clinical trial to examine the efficacy and safety of salmeterol xinafoate 42mcg bid, beclomethasone dipropionate 84mcg qid, and placebo in adolescent and adult subjects with mild to moderate asthma.
Pr. No. SLGA5015
238. A comparison of the safety and efficacy of 2 oral doses of PDA-641 (10mg and 30mg TID) and placebo in mild to moderate asthmatics.
Pr. No. 0805A-205-US
239. A five-way crossover clinical trial of single doses of salmeterol 25, 50, and 100mcg via the Diskus™ (multidose powder inhaler), albuterol Rotacaps 200mcg via Rotahaler, and placebo in pediatric subjects aged 4-11 years with asthma.
Pr. No. SLGA2016
240. Azelastine nasal spray market research study.
Pr. No. 362
241. Dose-ranging study of mometasone furoate nasal spray in the treatment of children (ages 6-11) with seasonal allergic rhinitis.
Pr. No. C95-161
242. A double-blind, placebo-controlled trial to determine the effects of zafirlukast on subjects with both asthma and seasonal allergic rhinitis.
Pr. No. 9188IL/0092
243. A double-blind comparison of the safety and efficacy of two doses of BAY x 7195 aerosol with placebo in patients with asthma.
Pr. No. D95-016-11
244. A validation study of the intraday and interday precision of methacholine challenge procedures.
Pr. No. 95/04
245. Objective and subjective measurements of the effectiveness of mometasone furoate nasal spray vs. placebo in patients with seasonal allergic rhinitis.
Pr. No. P95-219
246. A double-blind, placebo-controlled study to determine the efficacy and safety of 1, 10 and 100mg D7193 in adult asthma patients.
Pr. No. 120
247. A double-blind, placebo controlled trial to assess the safety and efficacy of zafirlukast and loratadine in subjects with seasonal allergic rhinitis.
Pr. No. 9188IL/0126
248. A phase II, placebo-controlled study to evaluate the safety and efficacy of anti-IgE recombinant humanized monoclonal antibody (rhuMAb-E25) in subjects with moderate to severe allergic asthma.
Pr. No. Q0694g

249. A study of the safety and efficacy of ABT-761 150mg, 300mg QD versus placebo in moderate asthma.
Pr. No. M95-411
250. A placebo-controlled, 12-week safety and efficacy study of albuterol dry powder inhaler and albuterol metered-dose inhaler in asthmatics.
Pr. No. DDPIAS-III-01-0694
251. A randomized study evaluating the effect of montelukast sodium to salmeterol in the inhibition of exercise-induced bronchoconstriction in adult asthmatics.
Pr. No. 064
252. A 6 and 12 month, open label, safety and efficacy study of HFA-143a beclomethasone dipropionate (BDP) in pediatric patients with asthma.
Pr. No. 1195-BRON
253. Efficacy and safety of mometasone furoate nasal spray in the treatment of acute episodes and recurrences of sinusitis.
Pr. No. C96-195
254. A placebo-controlled, parallel-group study of [R]-albuterol in the reversal of bronchoconstriction and in the management of asthma.
Pr. No. 051-024
255. Exercise challenge dose response study of HFA-134a butixocort propionate, CFC-11/12 beclomethasone dipropionate and HFA-134a placebo in patients with reversible obstructive airway disease.
Pr. No. 1219-BUTI
256. An open-label, 12-month, safety study of Sprios™ dry powder inhaler (albuterol sulfate) in asthmatics.
Pr. No. DDPIAS-III-02-0995
257. A Long-term, Open-label, Safety study of Ebastine 20mg in Patients with Perennial Allergic Rhinitis
Pr. #RP 64305-141
258. One-year, evaluator-blind safety study of mometasone furoate nasal spray vs. beclomethasone dipropionate in children (ages 6-11) with perennial rhinitis.
Pr. No. C96-091
259. A six-week dose response study of RPR 106541T 10 mcg bid, 50 mcg bid and 400 mcg bid versus beclomethasone dipropionate 168 mcg bid versus placebo in chronic asthma.
Pr. No RPR 106541T-202
260. A placebo-controlled study examining the effect of fluticasone propionate aqueous nasal spray 200 mcg qd used in conjunction with an antibiotic in allergic subjects with recurrent sinusitis.
Pr. No. FLTA 4015
261. Placebo-controlled, dose ranging study of mometasone furoate dry powder compared to beclomethasone dipropionate in the treatment of asthma in subjects previously maintained on inhaled corticosteroids.
Pr. No. C96-134
262. A Study of the Efficacy of Zileuton 1200mg BID, Controlled-Release (CR), and 600mg QID, Immediate Release (IR), and Placebo in Patients with Moderate Asthma.
Pr. #M95-337
263. A Single-Blind, Randomized, Parallel Group Comparison of the Efficacy and Safety of Beclomethasone Dipropionate Aqueous Nasal Spray Versus Cromolyn Sodium Nasal Solution Versus Placebo for Four Weeks in Subjects with Seasonal Allergic Rhinitis.
Pr. #BDPA 4001

264. A Comparative Bronchoprovocation Challenge Study of Two Albuterol Metered-Dose Inhalers in Patients With Stable Mild Asthma.
Pr. #94/11
265. Placebo-Controlled, Efficacy and Safety Study of Mometasone Furoate Dry Powder in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta-Agonists
Pr. #C96-186
266. START - Inhaled Steroid Treatment As Regular Therapy in Early Asthma, A Study of the Effect of Early Intervention With Long-Term Inhaled Budesonide (Pulmicort® Turbuhaler®) In Newly Diagnosed Asthma.
Pr. #SD-004-0111
267. A Double-Blind Placebo Controlled Pilot Trial to Determine the Efficacy of Cisapride in Improving Respiratory Symptoms and Pulmonary Function in Asthmatics with Gastroesophageal Reflux (GER).
Pr. # CIS-USA-84
268. A Named-Patient Safety Study of Pulmicort [Budesonide] Nebulizing Suspension in Severe, Oral Steroid-Dependent Asthmatic Patients Aged Six Months to Eight Years.
Pr. #04-3121
269. A Twelve-Month, Double-Blind, Between-Patient, Placebo-Controlled Trial Comparing the Safety, Tolerability and Efficacy of 12 mcg and 24 mcg Twice Daily Formoterol Dry Powder Capsules for Inhalation, Delivered by a Single-Dose Inhaler (Aeroliser™), in Children with Asthma in Need of Daily Treatment with Inhaled Bronchodilators and Anti-Inflammatory Treatment.
Pr. #049
270. A Dose-ranging, Safety and Efficacy trial with Zafirlukast (ACCOLATE) in the Treatment of Pediatric Subjects with Mild-to-moderate Asthma; Up to a 52 Week Open Label Safety Extension.
Pr. #9188IL-0139
271. A Double-Blind, Placebo-Controlled Study to Assess the Clinical Effect of Montelukast in Patients with Seasonal Allergic Rhinitis.
Pr. #068
272. An Open Multicenter Study for the Validation of a Caregiver Asthma Diary (Pediatric).
Pr. # EPO7001.010
273. A Comparison of the Onset of Action of Claritin-D and Semprex-D in Patients with Moderate to Severe Seasonal Allergic Rhinitis.
Pr. # SPX D-97-01
274. A Clinical Study of the Effects of Three Types of Adhesive Nasal Strips on Nasal Airflow Resistance.
Pr. #CL970003
275. The Cultural Adaptation into Hispanic of the Asthma Quality of Life Questionnaire (adult version).
Pr. #AQLQ
276. The Cultural Adaptation into Hispanic of the Rhinoconjunctivitis Quality of Life Questionnaire (adult version).
Pr. #95.3253
277. A Placebo-Controlled Parallel Study Comparing the Efficacy and Safety of Three Dosage Strengths of Fexofenadine HCl (15, 30 and 60 Mg BID) in Pediatric Patients (Ages 6 to 11 Years) in the Treatment of Seasonal Allergic Rhinitis.
Pr. #PJPR0066

278. A Placebo-Controlled Parallel Study Comparing the Efficacy and Safety of Fexofenadine HCl 120 MG and 180 MG QD in the Treatment of Autumn Seasonal Allergic Rhinitis.
Pr. #MO16455B/3081
279. An Evaluation of Quality of Life and Work, Study and Daily Activity Impairment Measures in Patients Receiving Fexofenadine HCl 120 MG and 180 MG in the Treatment of Autumn Seasonal Allergic Rhinitis.
Pr. #MO16455B/3004
280. The Evaluation of Three Norastemizole Doses (15 mg, 30, 45 mg) and Loratadine When Administered to Subjects with Seasonal Allergic Rhinitis.
Pr. #110-008
281. A Placebo-Controlled Evaluation of Histamine Skin Test Reactivity Following Single and Multiple Doses of Astelin® Nasal Spray.
Pr. #364/C970003
282. A Placebo-Controlled, Multicenter Study Evaluating the Effect of Montelukast Sodium Compared to Inhaled Beclomethasone Dipropionate in Adult Asthmatics.
Pr. #MK-070
283. A One-Day, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Clemastine Triple Combination (CTC), TheraFlu Sinus and Placebo in the Treatment of Seasonal Allergic Rhinitis.
Pr. #HSC-306
284. A Placebo-Controlled Study to Investigate the Efficacy and Safety of Inhaled Zanamivir (GG167) 10mg Administered Twice a Day for Five Days In the Treatment of Symptomatic Influenza A and B Viral Infections in Adolescents and Adults.
Pr. #NAIA 3002
285. An Evaluation of Pulmicort Respules (Budesonide Nebulizing Suspension) Versus Intal (Cromolyn sodium) Nebulizer Solution on Asthma-Related Outcomes in Children Two to Six Years Old.
Pr. #DX-RES-2000
286. A Placebo-Controlled, Comparison of Inhaled Fluticasone Propionate (88mcg BID) with Oral Zafirlukast (20mg BID) in Subjects With Mild to Moderate Asthma.
Pr. #FLTA 5001
287. A Comparative Study of Inhaled Fluticasone Propionate 88mcg BID Versus Zafirlukast 20mg BID in Asthmatic Subjects Who Are Currently Receiving Low Dose Inhaled Corticosteroids.
Pr. #FLTA 4035
288. A Comparative Study of the Efficacy and Safety of Zyrtec vs. Claritin and Placebo in the Treatment of Chronic Idiopathic Urticaria.
Pr. #L-0342
289. A Study of Albuterol Controlled Release Suspension in the Treatment of Children With Asthma.
Pr. #05
290. Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of Asthma in Subjects Previously Maintained on short-acting Inhaled Beta-Agonists.
Pr. #C97-226
291. Placebo-Controlled, Dose-Ranging Study of Mometasone Furoate HFA-227 Metered Dose Inhaler Compared to Beclomethasone Dipropionate (Vanceril 84 mcg Double Strength) in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids.
Pr. #C97-208-10

292. A Placebo-Controlled Study Examining the Effect of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD in Subjects with an Acute Episode of Recurrent Sinusitis.
Pr. #FLTA 4033
293. A Placebo-controlled, 12-week Safety and Efficacy Study of Beclomethasone Dipropionate Dry Powder Inhaler and Beclomethasone Dipropionate Metered-dose Inhaler in Asthmatics.
Pr. #DPIBDP-03
294. Dose Ranging Study of SCH 34117 in the Treatment of Patients with Seasonal Allergic Rhinitis.
Pr. #C98-001
295. A Comparison of Zafirlukast (ACCOLATE) with Placebo in Pediatric Subjects with Mild-to-Moderate Asthma.
Pr. #9188IL/0150
296. A Phase II/III Placebo-Controlled, Efficacy, Safety and Dose Response Study of Azmacort® (triamcinolone acetonide) HFA-134a Inhalation Aerosol 225 mcg, 450 mcg and 900 mcg Administered Once Daily for 12 Weeks in the Treatment of Mild Persistent and Moderate Persistent Asthma in 800 Adolescents and Adults.
Pr. #RG5016Y-204
297. A Study of the Efficacy and Safety of Tylenol® Allergy Sinus (AS) Compared with Claritin® in the Treatment of Seasonal Allergic Rhinitis
Pr. #97-034
298. A Placebo-Controlled Study to Investigate the Safety and Efficacy of Omeprazole, 10 mg qd and 20 mg qd in Preventing Heartburn.
Pr. #171
299. A Placebo-Controlled Study to Compare Concomitant Montelukast and Loratadine With Intranasal Beclomethasone in Patients With Seasonal Allergic Rhinitis.
Pr. #077
300. A Comparison of the Effect of Two Doses of Levalbuterol with Ventolin® on Pulmonary Function in Subjects with Mild-To-Moderate Asthma.
Pr. #051-027
301. Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate Dry Powder Inhaler in the Treatment of Asthma in Children Previously Maintained on Inhaled Corticosteroids.
Pr. #C97-300
302. Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate Dry Powder Inhaler in the Treatment of Asthma in Children Previously Maintained on Beclomethasone Dipropionate (Vanceril® 84 mcg Double Strength).
Pr. #C97-380
303. A Placebo-Controlled Comparison of the Safety and Efficacy of Claritin vs. Fexofenadine vs. Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis.
Pr. #P97-344
304. A Parallel-Group Chronic Asthma Study Comparing Montelukast With Placebo in 2- to 5-Year-Old Patients.
Pr. #072
305. A Long-Term Open-Label Study to Evaluate the Safety of HFA Flunisolide in Adult and Adolescent Patients with Mild to Moderate Asthma.
Pr. #ANC-MD-02-000
306. Efficacy and Safety of SCH 34117 in the Treatment of Patients With Seasonal Allergic Rhinitis.
Pr. #C98-223

307. Efficacy and Safety of SCH 34117 in the Patients With Seasonal Allergic Rhinitis.
Pr. #C98-224
308. Efficacy and Safety of 800 mcg or 400 mcg of Mometasone Furoate Nasal Spray or Placebo in the Treatment of Acute Episodes of Sinusitis.
PR # C97-251
309. A Study Comparing the Clinical Effect of Concomitant Montelukast+Loratadine with Montelukast, Loratadine, and Inhaled Beclomethasone in Patients With Chronic Asthma.
Pr. #074
310. A Phase III 7-month placebo-controlled trial with a 5-month open label extension period to assess safety and tolerability, steroid reduction, pharmacokinetics, and pharmacodynamics of subcutaneous rhuMAb-E25 in children (6-12 years) with allergic asthma requiring daily treatment with inhaled corticosteroids.
Pr. #rhuMAb-E25 01 010
311. The Evaluation of Three Norastemizole Doses (30mg, 60mg 90mg) and Loratadine When Administered to Subjects with Seasonal Allergic Rhinitis.
Pr. #110-024
312. One-Year Study of the Effects of Mometasone Furoate Dry Powder Inhaler versus Placebo on Growth of Children with Asthma.
Pr. #C97-384
313. Efficacy and Safety of SCH 34117 in the Treatment of Patients With Seasonal Allergic Rhinitis (Four Weeks Treatment).
Pr. #C98-225
314. A Double-Dummy, Comparison of Inhaled Fluticasone Propionate (88 mcg BID) versus Zafirlukast (20mg BID) over 12 Weeks in Subjects with Persistent Asthma.
Pr. # FAS40023
315. The Pharmacodynamics and Safety of Levalbuterol Syrup in Pediatric Subjects with Mild-to-Moderate Asthma.
Pr. #051-202
316. Long Term Safety of Mometasone Furoate HFA 227 Nasal Aerosol in Perennial Allergic Rhinitis.
Pr. #C97-302
317. A Comparison of the Ease of Teaching Correct Inhaler Technique and Patient Device Preference Between Pulmicort Turbuhaler® (budesonide inhalation powder) and Several Pressurized Metered Dose Inhalers in Patients with Asthma.
Pr. #DX-PUL-1002
316. A Double-Blind Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Montelukast Sodium (10mg QD) in Subjects Currently Receiving Beta Agonists Alone.
Pr. #FLTA4039
317. A Study Comparing the Efficacy and Safety of Fexofenadine HCl 120mg q.d., Cetirizine HCl 10 mg q.d., and Placebo q.d. in the Treatment of Perennial Allergic Rhinitis.
Pr. #M016455M/309
318. Phase II Placebo-Controlled Eight Week Study of Efficacy and Safety of Inhaled CP-325,366 in Adults with Persistent Asthma.
Pr. #264-101-5012
319. A Phase I Safety and Pharmacokinetic Study of IL-4R Comparing Two Aerosol Delivery Devices.
Pr. #013.0009

320. An Open-label Placebo-Controlled Study to Compare the Endocrine Effects of Aerobid Inhaler System (flunisolide), Flovent Inhalation Aerosol (fluticasone propionate), and Oral Prednisone in patients with Mild to Moderate Asthma.
Pr. #AER-MD-08-000
321. A Placebo-Controlled Study of Ro 64-0796 (also known as GS 4104) in Children with Influenza.
Pr. #WV15758
322. A Placebo-Controlled Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol 50mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination as Compared to Placebo in COPD Subjects.
Pr. #SFCA3007
323. A Placebo-Controlled Study of the Clinical Effect of Nebulized L-808,065 in Patients with Chronic Asthma.
Pr. #004-00
324. A Double-Blind Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Montelukast Sodium (10mg QD) in Subjects Currently Receiving Beta Agonists Alone
Pr. #FLTA4039
325. A Study Comparing the Efficacy and Safety of Fexofenadine HCl 120mg q.d., Cetirizine HCl 10 mg q.d., and Placebo q.d. in the Treatment of Perennial Allergic Rhinitis
Pr. #M016455M/3097
326. Phase II Placebo-Controlled Eight Week Study of Efficacy and Safety of Inhaled CP-325,366 in Adults with Persistent Asthma
Pr. #264-101-5012
327. A Phase I Safety and Pharmacokinetic Study of IL-4R Comparing Two Aerosol Delivery Devices
Pr. #013.0009
328. An Open-label Placebo-Controlled Study to Compare the Endocrine Effects of Aerobid Inhaler System (flunisolide), Flovent Inhalation Aerosol (fluticasone propionate), and Oral Prednisone in patients with Mild to Moderate Asthma
Pr. #AER-MD-08-000
329. A Placebo-Controlled Study of Ro 64-0796 (also known as GS 4104) in Children with Influenza
Pr. #WV15758
330. A Placebo-Controlled Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol 50mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination as Compared to Placebo in COPD Subjects
Pr. #SFCA3007
331. A Placebo-Controlled Study of the Clinical Effect of Nebulized L-808,065 in Patients With Chronic Asthma
Pr. #004-00
332. A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial to Assess the Effect of Zafirlukast (Accolate) 20mg Twice Daily when Administered with Food on Exercise-Induced Bronchoconstriction in Subjects with Asthma
Pr. #9188US/0025
333. An Evaluation of Safety and Tolerance of Cromolyn Sodium Following the Administration of a Nasal Solution to Pediatric Subjects
Pr. #M\3235\0002

334. A Parallel Study Comparing the Efficacy and Safety of Fexofenadine HCl 120 mg qd., 180 mg qd., Cetirizine 10 mg qd., and Placebo qd. In the Treatment of Perennial Allergic Rhinitis
Pr. #M016455M/3097
335. A Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous SB 240563 (250mg and 750mg) in Patients with Asthma
Pr. # SB 240563-006
336. Four-Week, Double-Blind, Safety and Efficacy Study of Beclomethasone Dipropionate Nasal Aerosol vs. Placebo in Children (Age 3-5) with Perennial and/or Seasonal Allergic Rhinitis
Pr. # C98-641-07
337. Dose Ranging Study of Mometasone Furoate HFA-227 nasal Aerosol in the Treatment of Patients with Seasonal Allergic Rhinitis
Pr. #C97-297
338. Safety and Efficacy Study of HFA-134a Albuterol Sulfate Delivered from a Press-and-Breathe MDI, HFA-134a Albuterol Sulfate Delivered from the Autohaler™ Inhalation Device, and HFA-Placebo in Patients with Asthma
Pr. #1332-SILV
339. Multi-Center, Randomized Comparison of the Efficacy, Onset of Action and Safety of a Single Dose of Fexofenadine 180 mg vs. Loratadine 10 mg vs. Placebo in Treating Seasonal Allergic Rhinitis in an Outdoor Environment
Pr. #M016455/4104
340. A 12-Week Comparison of Daily Doses of 100 mcg and 200 mcg of HFA-134a Beclomethasone Dipropionate in the Autohaler™ Device Versus Placebo in Pediatric Patients with Symptomatic Asthma
Pr. #1343-BRON
341. Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Adults
Pr. #013.0014
342. Development and Validation of a Questionnaire to Measure Health-Related Quality of Life in Adults with Allergic Rhinitis: The Relationship of Allergic Rhinitis, Sleep Quality and Daytime Fatigue
Pr. #MCS99001
343. A Twelve-Month Safety Study of 90mg Norastemizole in Subjects with Seasonal Allergic Rhinitis/Perennial Allergic Rhinitis Pr. #110-029
344. Phase IIA Multicenter, Randomized, Double-Blind, Double-Dummy, Active and Placebo-Controlled, Parallel Group, Dose-Response Study of the Efficacy, Safety, and Tolerability of Six Weeks Oral Dosing with CJ-13,610 Compared to Montelukast and Placebo in Adults with Persistent Asthma
Pr. #253-102
345. Efficacy and Safety of SCH 34117 and Cetirizine in the Treatment of Subjects with Seasonal Allergic Rhinitis
Pr. #P00384
346. A Placebo-Controlled Pilot Study Evaluating the Effects of Montelukast Sodium versus Salmeterol Xinafoate on Beta-agonist Induced Bronchodilation following Challenge – (Exercise) Induced Bronchoconstriction
Pr. #113-00
347. The Evaluation of Norastemizole (30 mg) and Loratadine When Administered to Subjects with Seasonal Allergic Rhinitis
Pr. #110-032

348. A Study to Assess the Growth Effects of a One-Year Course of Fluticasone propionate Aqueous Nasal Spray (200mcg QD) Versus Placebo in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis
Pr. #FNM40017
349. Efficacy and Safety of SCH 29851 8 mg QD in Subjects with Seasonal Allergic Rhinitis
Pr. #P00677
350. An open-label extension of rhuMAB-E25 treatment to children with allergic asthma who participated in the one-year study (rhuMAB-E25 Protocol No. 01 010)
Pr. #rhuMAB-E25 01 010 Extension 1
351. Efficacy and Safety of SCH 34117 + Pseudoephedrine, BID, vs its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis
Pr. #P00355
352. A Placebo-Controlled Comparative Trial of Albuterol Delivery by a New, Hand-Held, Ultrasonic Metered Dose Solution Inhaler (MSI) Compared to a Standard Metered Dose Inhaler (MDI) in Moderate Persistent Asthmatic Children (≥ 4 Years of Age and ≤ 12 Years of Age)
Pr. #7102-JAUS-02
353. Efficacy and Safety of SCH 34117 in Subjects with Seasonal Allergic Rhinitis and Concurrent Asthma
Pr. #P00214
354. A Phase II, Placebo-controlled, Study of AG7088 Nasal Spray, 2% Suspension for the Treatment of Natural Rhinovirus Infection in the General Population Including Patients with a History of Chronic Respiratory Disease
Pr. #AG7088-304
355. A Placebo-Controlled Study with SCH 34117 in the Treatment of Subjects > 12 Years of Age with Perennial Allergic Rhinitis
Pr. #P00217
356. A Placebo Controlled Comparative Trial of Albuterol Delivery by a New, Hand-Held, Ultrasonic Metered Dose Solution Inhaler (MSI) Versus a Standard Metered Dose Inhaler (MDI) in Patients with Bronchial Asthma
Pr. #7102-JAUS-04
357. A Placebo-Controlled, Cross-Over Study Evaluating the effect of a Single Dose of LDP-977 on the Acute Bronchodilator Response in Asthmatics
Pr. #L97799-018
358. An Open-Label, Multiple-Dose, Study to Evaluate the Safety of Beclomethasone Dipropionate and Reliability of the To-Be-Marketed Spiros Dry Powder Inhaler in patients with Asthma
Pr. #DPIBDP-07
359. A Parallel-Group, Placebo-Controlled, 12-Week Study of Fluticasone Propionate 44mcg BID and 88mcg BID delivered via CFC MDI and a Valved Holding Chamber with Facemask in Subjects with Asthma Age 24 months to 47 months
Pr. #FMS30058
360. Salmeterol vs. Montelukast for Asthmatics who Require more Therapy (SMART Study) A Randomized, Double-Blind Multicenter Study to Evaluate the Effect of Adding Either Montelukast Sodium or Salmeterol Xinafoate to Inhaled Fluticasone in Adult Asthmatics
Pr. #120
361. A Pilot Study to Evaluate Objective Measurements in Normal and Allergic Rhinitis Subjects
Pr. #X99-047

362. A Placebo-Controlled, Therapeutic Confirmatory Study Evaluating the Safety and Efficacy of 0.31 mg and 0.63 mg Levalbuterol and 1.25 mg and 2.5 mg Racemic Albuterol and Placebo
Pr. #051-031
363. A Placebo-Controlled, 12-Week Study of Fluticasone Propionate 44mcg BID and 88mcg BID delivered via CFC MDI and a Valved Holding Chamber with Facemask in Subjects with Asthma Age 6 months to 23 months
Pr. #FMS30059
364. Parallel-Group Study Comparing the Effect on Linear Growth of Montelukast With Placebo and Inhaled Beclomethasone in Pediatric Patients (Prepubertal, Tanner Stage I) With Mild Asthma
Pr. #097
365. Validation of a Nocturnal Rhinitis Quality of Life Questionnaire: Pre-Test Phase
Pr. #RG5029Y.US1.900
366. A Comparison of the Safety and Efficacy of Three Once Daily Doses of BAY 19-8004 with Placebo and Montelukast 10 mg Daily in Patients with Symptomatic Asthma
Pr. #100245
367. A Multicenter, Randomized, Double-Blind, Placebo-controlled Study of the Effect of Long-Term Treatment with Rhinocort® Aqua (Budesonide) Nasal Spray in Children with Perennial Allergic Rhinitis
Pr. #SD-005-0414
368. A Parallel-Group Study Evaluating the Protective Effects of the Salmeterol Xinafoate/Fluticasone Propionate Combination Product (50/100mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma
Pr. #SAS40024
369. A Parallel-Group Study Evaluating the Protective Effects of the Salmeterol Xinafoate/Fluticasone Propionate Combination Product (50/250mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma
Pr. #SAS40025
370. A Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients With Seasonal Allergic Rhinitis-Spring Study
Pr. #162-00
371. A Placebo-Controlled, Parallel-Group, Multiple-Dose, Multicenter, 12-Week Study to Compare the Safety and Efficacy of Beclomethasone Dipropionate via the To-Be-Marketed Spiros Dry Powder Inhaler to Vanceryl Metered-Dose Inhaler in Patients with Asthma
Pr. #DPIBDP-06
372. A Placebo-Controlled Study to Assess the Safety and Tolerability of Fexofenadine HCL 30 mg Twice a Day During Treatment of Children 2 through 5 Years of Age with Allergic Rhinitis
Pr. #M016455I/3112
373. A Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100 mcg DISKUS Inhaler BID versus Fluticasone Propionate 250 mcg DISKUS Inhaler BID in Adolescents and Adults with Moderate Persistent Asthma
Pr. #SAS40027

374. Clinical and Objective measurements of the Effectiveness of Desloratadine 5 mg vs. Placebo in Subjects with Symptomatic Seasonal Allergic Rhinitis (SAR)
Pr. #P00765
375. A Single Dose Study to Examine Anti-histamine and Sedation Potential of Concentrated Oral Liquid Formulations of Chlorpheniramine Maleate in Healthy Volunteers
Pr. #2000047
376. A Parallel Group Comparison of 200mcg Fluticasone Propionate Aqueous nasal Spray, Placebo and 10 mg Encapsulated Loratadine Administered (No more than Once Daily) As-Needed in Subjects with Seasonal Allergic Rhinitis
#FNM30030
377. A Multicenter, Placebo-Controlled, Open-Label Study to Evaluate the Safety of Omalizumab in Moderate to Severe Persistent Asthma Subjects Already Treated With Other Therapies (ALTO).
#Q2143g
378. An open-label extension study of Xolair™ (omalizumab) in moderate to severe, persistent, asthma subjects who completed study Q2143g (ALTO)
#2195g
379. Placebo-controlled, Parallel Group Study Assessing the Efficacy and Safety of Oral Fexofenadine HCl Tablets 30 mg Twice A Day in Pediatric Subjects (6 to 11 Years) in the Treatment of Seasonal Allergic Rhinitis
#M016455C/3212
380. Phase II Safety and Efficacy Study of Nebulized Recombinant Human IL-4 Receptor in Asthma
#013.0017
381. Randomized, Double-Blind, Double Dummy, Parallel Group Comparison of Fluticasone Propionate Inhalation Powder (50mcg BID) via DISKUS® with Oral Montelukast (5mg QD) Chewable Tablets in Children 6-12 Years of Age with Persistent Asthma
#FPD40012
382. A Placebo-Controlled, Environmental Study of PATANOL® Nasal Spray versus ASTELIN® in the Treatment of Seasonal Allergic Rhinitis
#C-00-33
383. A Phase IIa Cross-Over Study of Once Daily Inhalations of Three Doses of AlbuLast™ in Adults with Mild to Moderate Asthma
#AIR01-004
384. A Multicenter, Parallel-Group Study Investigating the Clinical Effect of L-858674 in Patients With Seasonal Allergic Rhinitis – A Pilot Study During the Fall Season
#003
382. Phase II Safety and Efficacy Study of Nebulized Recombinant Human IL-4 Receptor in Asthma Patients Using Inhaled Corticosteroids
#013.0019
383. A 2-Period Study in Subjects with Allergic Rhinitis to Assess the Response and Variability of Nasal Airway Resistance to Allergen Provocation
#002
387. Multi-Symptom Allergy Sinus Efficacy and Safety Study
#AD-99-02
388. Efficacy, Safety and Tolerability Study of Daily Dosing with Levalbuterol, Racemic Albuterol and Placebo in Pediatric Subjects 2-5 Years Old with Asthma.
#051-032

389. A Multicenter, Parallel-Group Study Comparing Montelukast With Placebo in Pediatric Patients Aged 2 Through 14 Years With Seasonal Allergic Rhinitis
#219-00
390. A Placebo and Loratadine Controlled Parallel-Group Study of Montelukast in Patients With Seasonal Allergic Rhinitis – Spring 2001 Study
#235-00
391. A Placebo-Controlled, Multi-Dose Study of the Potential Effects of Ciclesonide and Fluticasone Propionate on HPA-Axis in Adult Asthma Patients
#XRP1526B-102
392. A Double-Blind, Placebo-Controlled, Parallel Group Study of Four Doses of Loteprednol Etabonate Nasal Spray (100µg, 200µg, 400µg and 800µg) with Flonase® (200µg) as an Open Active-Control in the Treatment of Adults and Adolescents with Allergic Rhinitis Induced by Grass Pollen
#H-01075-3212
393. A Placebo-Controlled Efficacy and Safety Study of a Once-Daily PM and Twice Daily Regimens of Mometasone Furoate Administered Via Dry Powder Inhaler in Subjects With Asthma Who Were Previously Maintained On Inhaled Corticosteroids
#P01545
394. A Multicenter, Randomized, Parallel Group Study Of The Efficacy, Safety, Health Care Utilization and Health Related Quality Of Life With Nasacort® AQ (triamcinolone acetone aqueous) Nasal Spray and Flonase® (fluticasone propionate) Nasal Spray In The Treatment Of Patients with Seasonal Allergic Rhinitis #NAS.US1.435
395. A Study of the Efficacy and Safety of Zyrtec® (Cetirizine HCl) Syrup vs. Claritin® (Loratadine) Syrup vs. Placebo in the Treatment of Children with Seasonal Allergic Rhinitis #A1431009
396. A Randomized, Open Label, Cross Over Trial, Assessing Correct Use And Patient Preference of Fluticasone Propionate Inhalation Powder (100 mcg bid) via the Diskus Versus Fluticasone Propionate Aerosol via The Metered Dose Inhaler (88 mcg bid) in Subjects At Least 12 Years of Age with Persistent Asthma Currently Receiving Short Acting Beta Agonists Alone
#FPD40016
397. A Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Seasonal Allergic Rhinitis Over a 4-Week Treatment Period – Fall 2001
#240-00
398. Chronic-Dose Comparison of the Efficacy and Safety of Albuterol-HFA-MDI (SALAMOL™), Albuterol-HFA-BOI (SALAMOL EASI-BREATHE™) and PROVENTIL® HFA in Mild-to-Moderate Asthmatics
#BNP-301-4-167
399. A Phase III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of Ciclesonide Metered Dose Inhaler 100mcg/day, 200 mcg/day, and 400mcg/day (ex-valve) Administered Once Daily and 400mcg/day (ex-valve) Administered Twice Daily for 12-weeks in the Treatment of Mild to Moderate Persistent Asthma in Adolescents and Adults
#XRP1526B-322
400. A Placebo-Controlled Study to Assess the Safety and Efficacy of Dey Beclomethasone Dipropionate Monohydrate Nasal Spray 0.042% in Adolescent and Adult Patients with Seasonal Allergic Rhinitis
#DL-047

401. A placebo-controlled, 12-week trial evaluating the efficacy and safety of the fluticasone propionate/salmeterol DISKUS combination product 250/50mcg once daily fluticasone propionate/salmeterol DISKUS combination product 100/50mcg twice daily versus fluticasone propionate DISKUS 250mcg once daily versus placebo in symptomatic adolescent and adult subjects with asthma that are not controlled on short acting beta 2-agonists alone
#SAS30022
402. A Phase II, Placebo-Controlled, Double-Blind, Parallel Group, Dose-Finding Study to Evaluate the Effectiveness of 28 days of Treatment with LDP-977 in Adult Asthmatics
#M97700-023
403. A Single Center, Placebo-Controlled, Ascending-Dose Safety and Tolerability Study of INS37217 Aqueous Nasal Spray in Healthy Non-Rhinitic Volunteers and Healthy Volunteers with Perennial Allergic Rhinitis
#07-101
404. A Dose Response Comparison of the Topical Efficacy of HFA-134a Beclomethasone Dipropionate versus Fluticasone Propionate in Subjects with Persistent Asthma
#1434-BRON
405. A 12-week, placebo and active controlled, parallel group study evaluating the safety and efficacy of Formoterol fumarate (10 µg bid) delivered by the multi-dose dry powder inhaler (MDDPI) versus placebo versus albuterol pMDI qid in patients with persistent asthma
#CFOR258 F2302
406. A Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis
#246-00
407. 16-Week Comparison of Asthma Control in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50 mcg BID, Fluticasone Propionate DISKUS 100 mcg BID, Salmeterol Xinafoate DISKUS 50 mcg BID, or Oral Montelukast 10 mcg QD
#SAS40036
408. An efficacy and safety study of fluticasone propionate aqueous nasal spray (FP) in subjects with seasonal allergic rhinitis (SAR) #R1810221
409. Study of the efficacy and patient preference of albuterol delivered via the Pocketchamber™ (PC) versus the Aerochamber Plus™ (AC) in patients with asthma.
001
410. A double-blind, placebo-controlled, safety and efficacy study of three doses of INS37217 nasal spray in subjects with symptomatic perennial allergic rhinitis
#07-102
411. A multicenter, double-blind, randomized, parallel groups placebo-controlled study to assess the efficacy and safety of fexofenadine 120 mg bid in patients with mild to moderate persistent asthma
M016455P/3001
412. A multicenter, double-blind, randomized, placebo-controlled, parallel study to assess the safety and tolerability of fexofenadine HCL 30 mg in children with allergic rhinitis
#M016455T/3002

413. Phase II, randomized, three-arm, double-blind, placebo controlled, evaluation of the safety and efficacy of doxepin hydrochloride 0.04%, Civamide (zucapsaicin) 0.01%, and placebo nasal solution in the treatment of subjects with vasomotor rhinitis.
#WL-1002-03-01
414. An open-label, one year long-term safety study of ciclesonide metered dose inhaler 50 µg/Day to 200 µg/Day (Ex Valve) administered once daily or fluticasone dry powder inhaler (Flovent®Rotadisk®) 50 µg or 100 µg administered twice daily for the treatment of children with persistent asthma
#XRP1526B-344/68
415. A phase II study comparing the efficacy and safety of oral efletirizine immediate release (IR) 7 mg, 10 mg, and 15 mg tablets administered twice a day and oral efletirizine extended release (ER) 35 mg tablets administered once a day in the morning for two weeks versus placebo in subjects suffering from seasonal allergic rhinitis
#A00321
416. The evaluation of tecastemizole administered to subjects with seasonal allergic rhinitis
#110-073
417. Evaluation of a newly developed preference questionnaire for intranasal corticosteroids in patients with allergic rhinitis treated with Nasacort® AQ (triamcinolone acetonide) nasal spray 220 mcg and Nasonex® (mometasone furoate) nasal spray 200 mcg – a pilot study
#4006
418. A twelve-week, randomized, double-blind, double-dummy, placebo-controlled trial of Symbicort™ (80/4.5 mcg) versus its mono products (budesonide and formoterol) in children (>12 years of age) and adults with asthma
#SD-039-0716
419. A phase IIIa, multi-center, randomized, double-blind, parallel-group, placebo-controlled study on the efficacy and safety of fexofenadine HCL 180 mg once daily in chronic idiopathic urticaria #M016455A/4121
420. An efficacy and safety study of levalbuterol, racemic albuterol and placebo in subjects twelve years of age and older with asthma #051-353
421. A randomized, placebo-controlled, crossover study to assess the antihistamine activity and sedation potential of a new loratadine lingual spray formulation versus Claritin® tablets in healthy volunteers #001
422. A multicenter, randomized, double-blind, double-dummy, placebo controlled, parallel group, four-week study assessing the efficacy of fluticasone propionate aqueous nasal spray 200 mcg QD versus montelukast 10mg QD in adolescent and adult subjects with asthma and seasonal allergic rhinitis who are receiving concurrent open-label Advair Diskus[†] 100/50 mcg BID
#SAM40066
423. A placebo- and active-controlled efficacy and safety study of a once-daily fixed combination tablet of desloratadine 5 mg/pseudoephedrine 120 mg (SCH483 [5/120]) in subjects with seasonal allergic rhinitis
#P01861

424. A randomized, multicenter, placebo-controlled parallel group study of four months duration per patient treatment to evaluate the safety and efficacy of treatment with 24 µg b.i.d. and 12 µg b.i.d. formoterol, double-blind, and 12 µg b.i.d. formoterol with additional on-demand formoterol doses, open-label, in adolescent and adult patients with persistent stable asthma
#CFOR258D2307
425. A randomized, double-blind, placebo-controlled trial of Astelin® (azelastine hydrochloride) nasal spray, Clarinex® (desloratadine) and Astelin® nasal spray plus Claritin® (loratadine) in patients with seasonal allergic rhinitis #414
426. A placebo-controlled, efficacy and safety study of olopatadine nasal spray for the treatment of seasonal allergic rhinitis
#C-02-37
427. A multicenter, double-blind, randomized, parallel study comparing the efficacy and safety of fexofenadine 120 mg BID, fexofenadine 240 mg QD, and placebo in subjects with perennial allergic rhinitis
#M016455TM/3001
428. A multicenter, randomized, parallel-group, double-blind efficacy and safety study of INS37217 nasal spray versus placebo in subjects with perennial allergic rhinitis
#07-105
429. A randomized, double-blind, placebo-controlled trial of Astelin® (azelastine hydrochloride) nasal spray 137 mcg plus Allegra (fexofenadine hydrochloride 60 mg) in patients with seasonal allergic rhinitis
#415
430. A randomized, double-blind, placebo-controlled trial of Astelin® (azelastine hydrochloride) nasal spray 137 mcg at a dosage of one spray per nostril twice daily in patients with seasonal allergic rhinitis
#420
431. An open label pilot study of Astelin® (azelastine hydrochloride) nasal spray 137 mcg in the treatment of nasal congestion in patients with seasonal allergic rhinitis
#421
432. Distribution of the clearance and terminal-phase half-life of tecastemizole 30 mg (population pharmacokinetic screen)
#110-083
433. A multicenter, double-blind, randomized study investigating the clinical effect of montelukast on allergic rhinitis in patients with seasonal allergic rhinitis and chronic asthma – Spring 2003 study
#269-00
434. An efficacy and safety study of levalbuterol 90 mcg, racemic albuterol 180 mcg and placebo in subjects twelve years or older with asthma
#051-355
435. Efficacy and safety of 200 mcg QD or 200 mcg BID mometasone furoate nasal spray (MFNS) vs. amoxicillin vs. placebo as primary treatment of subjects with acute rhinosinusitis
#P02683
436. A randomized, double-blind, parallel-group multicenter efficacy and safety phase IIB pilot study of esomeprazole 40mg twice daily versus placebo twice daily in adult asthmatics treated for 4 months
#SD-NEE-0003

437. A comparison of fexofenadine HCL 180 mg, desloratadine 5 mg and placebo in suppression of wheal and flare induced by histamine
#M016455A/4145
438. An open-label, multi-center study to evaluate the performance and patient satisfaction of fluticasone propionate/salmeterol HFA with counter in asthma or COPD subjects at least 12 years of age
#SAS30033
439. An open-label, multi-center study to evaluate the performance and patient satisfaction of albuterol HFA with counter in asthma or COPD subjects at least 4 years of age
#SB030003
440. Term safety study of olopatadine nasal spray
#C-01-92
441. A twelve week, randomized, double-blind, parallel group trial comparing the efficacy, safety and tolerability of a 20mg daily dose of IPL512, 602 oral tablets to placebo in patients with mild to moderate persistent asthma
#AVE0547A/2001
442. A randomized, double-blind, placebo-controlled multicenter, parallel-group dose-response study evaluating the safety and efficacy of oral NGD 2000-1 dibesylate tablets in patients with mild to moderate asthma
#NC-00-004
443. Dose ranging study of Ro 27-2441 in patients with persistent asthma not treated with inhaled corticosteroids.
#BA16631-A
444. A multicenter, parallel study comparing the efficacy and safety of PULMOCORT RESPULES® (budesonide inhalation suspension) at 0.5 mg, QD, 1.0 mg QD, 1.0 BID, 2.0 BID and PULMICORT TURBUHALER ® (budesonide) at 400 mcg BID in adolescents (12 Years of Age and Older) and adults with moderate to severe asthma
#SD-004-0764
445. A parallel-group study investigating the clinical effect of L-000888839 in patients with seasonal allergic rhinitis – a pilot study during the fall season
#005
446. A 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long term treatment in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS BID or fluticasone propionate DISKUS BID (or placebo BID if asymptomatic)
#SAM40086
447. A placebo-controlled, parallel-group study investigating the clinical effects of montelukast in patients with perennial allergic rhinitis
#265
448. A twelve-week, active-controlled study of SYMBICORT® pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma – SPROUT
#SD-039-0725
449. A twelve-week, placebo- and active-controlled study of SYMBICORT® pMDI administered once daily in adults and adolescents with asthma – STEM
#SD-039-0726
450. Qualitative assessment of patient diary questions to assess patient perception of the onset of effect if asthma medication using cognitive debriefing methodology.
#A2-3269

451. 3-week, open-label, uncontrolled, multicenter study evaluating the functionality of the Foradil[®] Certihaler[®] device in patients with asthma
CFOR258F2304A
452. Efficacy and Safety of 200mcg QD or 200mcg BID Mometasone Furoate Nasal Spray (MFNS) vs. Amoxicillin vs. Placebo as Primary Treatment of Subjects with Acute Rhinosinusitis
P02692
453. A 1 year, randomized, double-blind, parallel-group, placebo-controlled, multicenter evaluation of efficacy, safety, pharmacokinetics and pharmacodynamics of omalizumab in children (6 - <12 years) with moderate-severe, persistent, inadequately controlled allergic asthma.”
#CIGE025AIA05
454. Psychometric Evaluation of Patient Satisfaction with Asthma Treatment
#HRA 23-371B
455. A Multicenter, double-blind, placebo-controlled, randomized, parallel-group study to evaluate the clinical effect of oral Montelukast versus placebo during the allergy season in patients with seasonal aeroallergen sensitivity and chronic asthma which is also active during allergy season
#289
456. A Multicenter, Randomized, Double-Blind Parallel Group Study of the Effects of Ciclesonide HFA-MDI 640 µg/day & beclomethasone HFA-MDI 640 µg/day on lens opacification in adult subjects w/ moderate to severe persistent asthma
#XRP1526B – 3027
457. A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Mast Cell Inhibitor, R-926112, in Patients with Symptomatic Seasonal Allergic Rhinitis in a Park Setting
#R-926112-004
458. A randomized, controlled study of roflumilast (250 mcg and 500 mcg) versus placebo in patients with asthma. A 24-week, multicenter, multinational, double-blind, parallel group clinical study
#BY217/M2-023
459. Ability to swallow with and without the aid of a pill cup in pediatrics subjects ages >6 to <12 years of age
#M016455C/6001
460. A 3-week, open-label, uncontrolled, multicenter study evaluating the functionality of the Foradil[®] Certihaler[®] device in patients with asthma
#CFOR258 F2306
461. 12 week study to assess the efficacy and safety of Symbicort[®] pMDI 160/4.5 µg x 2 actuations once-daily (QD) compared to Symbicort pMDI 80/4.5 µg x 2 actuations QD, Symbicort pMDI 80/4.5 µg x 2 actuations twice-daily (BID) and to budesonide pMDI 160 µg x 2 actuations QD in asthmatic subjects 12 years of age and older
D5896C0001
462. A placebo controlled study of the efficacy and safety of desloratadine vs. fexofenadine 180 mg. in the treatment of subjects with symptomatic seasonal allergic rhinitis (SAR)
P04053-11
463. Pediatric Questionnaire on Asthma Control: Initial Validation Study
GHO102199

464. Crossover study comparing the effect of L-000888839 with placebo & concomitant administration of L-000888839 plus montelukast in adults with chronic asthma
#008
465. A placebo-controlled, dose ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 ug) delivered via a multiple dose inhaler, and 1 dose of QAB149 (400 µg) delivered via a single dose inhaler, in adult and adolescent patients (12 – 75 years old inclusive) with stable, persistent asthma
CQAB149A2216
466. A four-week, placebo-controlled, study of ventolin HFA MDI delivered TID with facemask and valved holding chamber (Aerochamber Plus;) in subjects birth to <24 months in age with symptoms of bronchospasm (i.e. wheeze, cough, dyspnea or chest tightness) consistent with obstructive airways disease.
SB030001
467. A Phase 3 clinical trial designed to assess the efficacy and safety of ciclesonide applied as a nasal spray at three dose levels (100 mg, 200mg, or 25mg, once daily) in the treatment of perennial allergic rhinitis (PAR) in patients 6–11 years of age
BY9010/M1-403
468. Pharmacodynamics of the 88 mcg BID dose of the hydrofluoroalkane propellant formulation of inhaled fluticasone propionate following administration via the metered-dose inhaler in pediatric subjects 4 to 11 years of age with asthma
FAP 19052
469. A preference evaluation of Nasonex nasal spray (unscented vs. Flonase nasal spray (scented) in subjects with symptomatic allergic rhinitis (AR) single-dose cross-over
P04207
470. A placebo-and active-controlled (ciclesonide metered dose inhaler), dose range finding study of ciclesonide administered by dry powder inhaler (Ultrahaler[®]) in adult and adolescent patients with persistent asthma.
#AVE2635A/2001
471. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100 mcg for 4 weeks in adult and adolescent subjects (12 years of age) with perennial allergic rhinitis (PAR)
#FFR30002
472. Randomized double-blind trial of Astelin[®] (azelastine hydrochloride) nasal spray compared to Zyrtec[®] (cetirizine) in patients with seasonal allergic rhinitis
#MP 426
473. A randomized, double-blind, placebo-controlled study evaluating the effects of MN-001 in subjects with mild to moderate asthma
#MN-001-CL-001
474. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of once-daily, intranasal administration of GW685698X aqueous nasal spray 50mcg and 100mcg for 12 weeks in pediatric subjects ages 2 to <12 years with perennial allergic rhinitis (PAR)
#FFR30008
475. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 50mcg and 100mcg for 2 weeks in pediatric subjects Ages 2 to <12 years with seasonal allergic rhinitis (SAR)
#FFR100010

476. Randomized, double-blind, placebo-controlled, single-dose, 3-period crossover study to determine the effect of PLA-902 on exercise-induced bronchoconstriction
#PLA-902
477. Pilot efficacy and safety field trial of Desloratadine administered concomitantly with Oxybutynin, in subjects with seasonal allergic rhinitis and post-nasal drip
#SP4258
478. Safety and efficacy of olopatadine hydrochloride nasal spray in pediatric patients
#C-04-20
479. Safety and bioequivalence of Triamcinolone Acetonide Nasal Spray compared w/ Nasacort AQ[®] nasal spray 55 mcg in the relief of signs & symptoms of SAR
#CPL-404
480. A randomized, double-blind, placebo-controlled, parallel-group study of ciclesonide metered-dose inhaler administered at a daily dose of 160 ug either in a once-daily (160 ug qd) or a twice-daily (80 ug bid) regimen for 12 weeks in adults and adolescents with mild to moderate persistent asthma treated previously with inhaled corticosteroids
#XRP1526B/3030
481. A 3-week multicenter study investigating patient use and functionality of the Foradil[®] Certihaler[®] device in patients with asthma
#CFOR258F2309
482. A multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg administered either in a once-daily in the morning regimen (160 µg qd AM) for 16 weeks or in a 160 µg AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80 µg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids
#XRP1526B/3031
483. A phase II multi-center, randomized, double-blind, active and placebo--controlled 7 day study of mast cell inhibitor, R926112, in patients with symptomatic seasonal allergic rhinitis
#C-926112-005
484. Qualitative Research Into Asthma Control
#25-586A
485. A placebo- and active-controlled, parallel-group, dose-finding study of formoterol fumarate given by dry powder inhalation using the Ultrahaler[®] in adult and adolescent patients with persistent asthma
#AVE2635A-2003
486. Randomized, multicenter, crossover study to evaluate sensory attributes of olopatadine 0.6% nasal spray and Astelin[®] in patients with allergic rhinitis
#C-03-49
487. A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair[®] DISKUS 250/50 mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults with Mild Persistent Asthma
#NONE0-I-00081
488. A Phase III Multicenter Study to Demonstrate the Sensitivity and Specificity of Aridol (Mannitol) Challenge to Predict Bronchial Hyperresponsiveness as Manifested by a Positive Exercise Challenge in Subjects Presenting with Signs and Symptoms Suggestive of Asthma but Without a Definitive Diagnosis
#DPM-A-305

489. Childhood asthma control test: Longitudinal validation study.
8ADA106614
490. Efficacy and safety of combination Loratadine/Montelukast QD vs Pseudoephedrine and placebo in the treatment of subjects with seasonal allergic rhinitis.
#P04095
491. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily intranasal administration of GW685698X aqueous nasal spray 100mcg for 6 weeks in adult and adolescent subjects 12 years of age and older with perennial allergic rhinitis (PAR).
FFR106080
492. Assessment of safety, tolerability, and pharmacokinetics of Zileuton Injection in patients with asthma.
CTI-04-C05-201
493. A multicenter, randomized, double-blind, triple dummy, placebo-controlled, parallel group, four-week study assessing the efficacy of fluticasone propionate aqueous nasal spray 200 mcg QD versus Montelukast 10 mg QD in adolescent and adult subjects with asthma and seasonal allergic rhinitis who are receiving Advair DISKUS[®] 100/50mcg BID or placebo BID.
#ADA103578
494. Randomized, double-blind, placebo-controlled trial of the safety and efficacy of MP03-33 in patients with seasonal allergic rhinitis.
430
495. Psychometric evaluation of the asthma control outcome and risk assessment measures.
A2-3721
496. A placebo-controlled, parallel-group, clinical trial designed to assess the safety and efficacy of Ciclesonide (200 mcg and 100 mcg, once daily) applied as a nasal spray for two weeks in the treatment of seasonal allergic rhinitis (SAR) in patients 6 to 11 years of age.
BY9010/M1-417
497. A Multi-Center, No Drug Treatment, Cross-Sectional Survey Study to Develop and Validate the Rhinitis Control Assessment Questionnaire (RCAQ) in Adult and Adolescent Subjects 12 Years of Age and Older with Non-Infectious Allergic Rhinitis
FFU 108675
498. Pilot polysomnography study in subjects with seasonal allergic rhinitis who report sleep disturbances and daytime somnolence
#P04827
499. A Randomized, Cross-Over Design Study Evaluating a Traditional Paper Symptom Diary vs. the VOCEL[®] Mobile Diary in Subjects 12 years and Older with Mild to Moderate Persistent Asthma Receiving Alvesco[®] 80 µg BID
CICLE-L-01335
500. Double-Blind Multi-Centre, Placebo-Controlled, Clinical Study to Evaluate the Clinical Equivalence of 128 mcg of Budesonide Nasal Spray (Apotex Inc., Canada) vs. 128 mcg of Rhinocort Aqua[®] Nasal Spray (AstraZeneca, USA) for the Indication of Seasonal Allergic Rhinitis
BUDE-NASO-01NB01-CE
501. Psychometric Evaluation of the Asthma Control Outcome and Risk Assessment Measures
UBC A2-3721C

502. A multicenter, randomized, double-blind, placebo-controlled parallel group 8-week study to evaluate the efficacy and safety of chewable Montelukast when initiated at the start of the school year in pediatric patients with chronic asthma
340-00
503. A Clinical Study to Evaluate the Safety and Efficacy of Claritin 12-Hour 5 mg Loratadine Tablet BID vs. Placebo Tablet in the Treatment of Allergic Rhinitis
CL2006-03
504. An eight week, randomized, double-blind, parallel group, multicenter trial comparing the efficacy and safety of Oral IPL512,602 to placebo in subjects with moderate to severe persistent asthma inadequately controlled on inhaled corticosteroids
2002
505. A Patient Preference Evaluation Study of Fluticasone Nasal Spray and Fluticasone Propionate Aqueous Nasal Spray in Subjects with Allergic Rhinitis
FFU108556
506. A phase3, double-blind, placebo-controlled, multi-center, randomized study evaluating the safety and efficacy of SPRC-AB01, Tobramycin Solution for nasal inhalation, in post-surgical subjects with chronic rhinosinusitis
SPRC-AB01-003
507. Safety Study of Olopatadine Nasal Spray
C-05-69
508. A placebo-controlled, stratified, multicenter, 12-week study comparing the safety and efficacy of fluticasone and formoterol combination (FlutiForm™ 100/10µg or 250/10µg twice daily) in a single inhaler (SkyePharma HFA pMDI) with the administration of placebo of fluticasone (100/10µg or 250/10µg twice daily) and formoterol (10µg twice daily) alone in adult patients with asthma
2028-3-004
509. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Multiple Dosing Regimens of Nasal CO2 in the Treatment of Allergic Rhinitis
C211
510. A randomized, double-blind, placebo controlled, 3 arm, parallel group, phase 2 study investigating the efficacy, tolerability and pharmacokinetics of MAP0010 in asthmatic children and adolescents
0010-CL-P201
511. A double-blind placebo-controlled, randomized, parallel-group, single-site study of Nasonex Nasal Spray in subjects with mild-moderate obstructive sleep apnea-hypopnea (OSAHS) associated with perennial allergic rhinitis (PAR) using home-monitored cardio-respiratory methodology # P04726
512. Assessment of the content validity of the asthma Quality of Life Questionnaire (AQLQ) in patients with moderate to severe asthma
A2-4158 000
513. A Placebo-Controlled Study of the Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure
P04295
514. Inhaler Technique Evaluation for Pediatric Asthma
HRA 25-587A

515. A comparative study of the efficacy and tolerability of maintenance treatment of patients with mild/moderate persistent asthma with Asmanex Twisthaler 220 mcg QD PM versus “Asmanex” Placebo QD PM
P04654
516. Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 years or older) with Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy
#BY9010/M1-490
517. Study to Evaluate Efficacy & Safety of GW685698X 200mcg BID GW685698X 200mcg & 400mcg QD in AM, & GW685698X 200mcg & 400mcg QD in the Evening Compared w/ Pbo for 8 Wks in Subjects 12+ w/persistent asthma
#FFA106783
518. Placebo Controlled Study of Nasonex in the Treatment of Seasonal Allergic Rhinitis
#P05067
519. A Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 317 in Subjects With Moderate to Severe Asthma
#20060161
520. Randomized, double-blind, placebo controlled trial of the safety and efficacy of MP03-36 and MP03-33 in patients with perennial allergic rhinitis
#MP434
521. Active-Controlled Trial of the Safety and Tolerability of MP03-36 in Patients with Perennial Allergic Rhinitis
#MP436
522. A randomized, double-blind, placebo controlled, 3 arm, parallel group, phase 2 study investigating the efficacy, tolerability and pharmacokinetics of MAP0010 in asthmatic children and adolescents over 6 weeks
#MAP0010-CL-P201
523. A Double-Blind, Placebo Controlled, Randomized Study to Evaluate the Clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma Which is Also Active During Allergy Seasons in Pediatric Patients with Seasonal Aeroallergen Sensitivity
#336
524. A two-week, randomised, double-blind study assessing the Onset of Effect Questionnaire (OEQ) administered daily versus weekly in adult subjects (≥ 18 years of age) with mild to moderate asthma, receiving SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice daily or budesonide HFA pMDI 80 μg x 2 actuations twice daily
#D5896C00023
525. A double-blind, randomized, placebo-controlled, dose-ranging study to assess the efficacy and safety of ciclesonide HFA nasal aerosol in adult and adolescent patients 12 years and older with seasonal allergic rhinitis (SAR)
#BY9010/M1-602
526. A 26-week placebo-controlled efficacy and safety study of mometasone furoate/formoterol fumarate combination formulation compared with mometasone furoate and formoterol monotherapy in subjects with persistent asthma previously treated with low-dose inhaled glucocorticosteroids
#P04073

527. A 26-week placebo-controlled efficacy and safety study of mometasone furoate/formoterol fumarate combination formulation compared with mometasone furoate and formoterol monotherapy in subjects with persistent asthma previously treated with medium-dose inhaled glucocorticosteroids
#P04334
528. A 26 week treatment, randomized, multi center, double blind, double dummy, parallel-group study to assess the safety of indacaterol (300 and 600 µg o.d.) in patients with moderate to severe persistent asthma using salmeterol (50 µg b.i.d.) as an active control
#CQAB149B2338
529. Randomized, double-blind, placebo-controlled trial of the safety and efficacy of MP03-36 in patients with seasonal allergic rhinitis
#439
530. A phase II, double-blind, placebo-controlled, multi-center, randomized study evaluating the safety and efficacy of SPRC-AB01, tobramycin solution for nasal inhalation, in post-surgical subjects with chronic sinusitis
SPRC-AB01
531. A randomized, double-blind, placebo-controlled study to evaluate the efficacy of Ziluten controlled-release (CR) tablets versus placebo in adult patients with asthma poorly controlled on moderate dose inhaled corticosteroids (ICS)
CTI-03-C07-401
532. Efficacy and safety of concurrent administration of mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray administered once daily (QD) vs. oxymetazoline twice daily (BID), mometasone furoate QD, and placebo in the treatment of subjects with seasonal allergic rhinitis
P04500
533. A randomized, double-blind, placebo-controlled, active comparator, one-week, cross-over, multicenter study to evaluate the efficacy and patient preference of nasal spray characteristics of once-daily, intranasal administration of 110mcg fluticasone furoate nasal spray and 200mcg fluticasone propionate nasal spray in adult subjects with seasonal allergic rhinitis
FFU105927
534. Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy (Bronchodilation) and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (2 µg, 5 µg, 10 µg, 20 µg) Delivered by the Respimat® Inhaler in Patients with Asthma
#1222.6
535. Efficacy and safety of 200 mcg BID mometasone furoate nasal spray (MFNS) vs placebo as adjunctive treatment to antibiotics in relief of symptoms of acute bacterial sinusitis
P04824
536. A randomized, double blind, placebo controlled, parallel group, study investigating the safety and efficacy over 12 weeks treatment period of MAP0010 in asthmatic infants and children 12 months to 8 years of age
#0010-CL-P301
537. Validation of patient-reported outcomes in patients with moderate to severe asthma
#20070787

538. A randomized, double-blind, placebo-controlled, parallel-group study comparing the bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (APOTEX, INC.) to that of Nasacort® AQ Nasal Spray (Aventis Pharmaceutical Products, Inc.) in the treatment of seasonal allergic rhinitis
TRIA-NASO-05RB02-CE
539. Test for respiratory and asthma control in kids (TRACK)
CTI-07-503
540. Safety and efficacy of olopatadine HCl nasal spray in 6-11 year old patients
C-07-01
541. Evaluation of successful use of a breath-actuated inhaler: a prospective, randomized, open-label, 2 arm parallel study
IXR-304-04-167
542. Exploratory study to measure the effect of Breathe Right Strips on nasal patency in healthy children
B3340547
543. Randomized, double-blind trial of MP29-02 nasal spray compared to placebo, azelastine hydrochloride nasal spray, and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis
#4002
544. A randomized, double blind, active controlled, phase 3 extension study investigating the safety and efficacy over 40 weeks of 2 doses of MAP0010 in asthmatic infants and children (aged 12 months to 8 years at enrollment into the MAP0010-CL-P301 study) #0010-CL-P301X
545. A multi-center, randomized, double blind, placebo controlled parallel group study of the safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d. dosing in children aged 2 to 6 years suffering from allergic rhinitis or chronic urticaria of unknown origin
A00426
546. A randomized, double-blind, double-dummy, placebo-controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily and salmeterol 50mcg administered twice daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma.
B2C109575A
547. Placebo-controlled study of mometasone furoate nasal spray (MFNS) 200 mcg QD in the relief of nasal congestion associated with seasonal allergic rhinitis (SAR)
P05529
548. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study Comparing the Safety and Efficacy of MAP0010 (0.135 mg And 0.25 mg) with Placebo in 12-Month-Old to 8-Year-Old Children with Asthma
#0010-CL-P302
549. Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults & Adolescents 12 and Older w/ PAR
#FFR110537
550. A randomized, double-blind, active-controlled, Phase 3 extension study investigating the safety and efficacy over 40 weeks of 2 doses of MAP0010 in asthmatic children (12 months to 8 years old at the time of enrollment into the MAP0010-CL-P301 Study)
0010-CL-P301X

551. A double-blind, randomized, multicenter, cross-over evaluation of the sensory attributes of Olopatadine 0.6% and Azelastine 137 mcg nasal sprays in patients with allergic rhinitis (Sensory II)
SMA-08-21
552. Double-blind, randomized, placebo-controlled, multi-center, parallel group, dose-ranging study of MK0633 in adult patients with chronic asthma
007
553. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide in the Treatment of Seasonal Allergic Rhinitis
C215
554. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Sublingual Immunotherapy (SLIT) in Adults Sensitized to the Standardized Allergenic Extract, Cat Hair (*Felis domesticus*)
ALI002-08
555. A double-masked, randomized, parallel group comparison of seasonal allergic rhinitis treatment with olopatadine 0.6% and azelastine 0.1% when treatments are used in combination with fluticasone propionate 50 mcg nasal spray
#SMA-08-23
556. A multicenter, randomized study starting with a 4-week, 2-way crossover double-blind treatment phase comparing the efficacy and safety of Combivent® CFC MDI to albuterol HFA MDI followed by a 4-week open-label Combivent Respimat® treatment phase when all study drugs are used for symptom relief “as needed” in patients with moderate-to-severe asthma (GINA 2007 Treatment Steps 3 to 5)
#1012.57
557. A double-blind, randomized, placebo-controlled, parallel-group, multi-center, dose-range-finding study to assess the efficacy and safety of BDP HFA nasal aerosol in adult and adolescent patients (12 years and older) with seasonal allergic rhinitis (SAR)
BDP-AR-201
558. Safety of PATANASE® Nasal Spray in Patients with Perennial Allergic Rhinitis
C-08-32
559. Pulmonary safety of Staccato® Loxapine for inhalation in patients with asthma
AMDC-004-105
560. A randomized, double blind, placebo controlled, parallel group, study investigating the safety and efficacy over 12 weeks treatment period of MAP0010 in asthmatic infants and children 12 months to 8 years of age
MAP0010-CL-P301
561. A randomized, double-blind, active-controlled, Phase 3 extension study investigating the safety and efficacy over 40 weeks of 2 doses of MAP0010 in asthmatic children (12 months to 8 years old at the time of enrollment into the MAP0010-CL-P301 Study)
MAP0010-CL-P301X
562. Randomized, double-blind trial of MP29-02 nasal spray compared to placebo, azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis
MP4006
563. A phase 4, multicenter, double-blind, randomized, placebo-controlled study of the safety and tolerance of Regadenoson in subjects with asthma or chronic obstructive pulmonary disease (COPD)
#3606-CL-3001

564. A double-blind, randomized, placebo-controlled, parallel group exploratory study of the safety and efficacy of JNJ-39758979 in the treatment of adults with persistent asthma
39758979ASH2001
565. A double-masked, randomized, multi-center study examining the safety and efficacy of olopatadine 0.6% and azelastine 137 mcg nasal sprays in a two-week vasomotor rhinitis trial
SMA-09-03
566. Phase 2b, randomized study to evaluate the efficacy and safety of subcutaneous MEDI-258 in adults with uncontrolled asthma
CP198
567. Randomized, double-blind, placebo-controlled trial of the safety and efficacy of mp03-36 (0.15% solution) and mp03-33 (0.10% solution) in children ages >6 to <12 with perennial allergic rhinitis
MP441
568. A randomized, double-blind, placebo controlled, multiple dose phase 2 study to determine the safety and efficacy of amg 853 in subjects with inadequately controlled asthma
#20080615
569. A 6- month randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of once daily ciclesonide HFA nasal aerosol (80 and 160 µg) in the treatment of perennial allergic rhinitis (PAR) in subjects 12 years and older
#060-633
570. A double-blind, randomized, placebo-controlled, 5-way crossover, multicenter, single dose, dose-ranging study to compare the efficacy and safety of Albuterol Spiromax and ProAir® HFA in adult and adolescent subjects ages 12 and older with persistent asthma
#ABS-AS-201
571. A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler® (500/400 µg) and mometasone furoate Twisthaler® (400 µg) in adolescent and adult patients with persistent asthma.
CQMF149A2210
572. A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control.
#CQAB149B2357
573. A long-term, randomized, double-blind study of the safety, tolerability and efficacy of aclidinium bromide at two dosage levels when administered to patients with moderate to severe, stable chronic obstructive pulmonary disease.
#LAS-MD-35
574. A Randomized, Double-blind, Single-dose Efficacy Study of 0.05% Oxymetazoline Fine Mist Spray in Adult Subjects Suffering from Nasal Congestion.
#2010042
575. Qualitative Interviews with Patients who have Asthma.
#10-1378A
576. A 6-Month Open-Label, Long-Term Safety Extension Study of Once Daily Ciclesonide HFA Nasal Aerosol (160 µg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older.
#060-635
577. A Multi Center 52-Week Study to Assess the Safety of Albuterol *Spiromax*® in Subjects with Asthma.
#ABS-AS-306

578. A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax versus Placebo in Subjects 12 years and older with Persistent Asthma.
ABS-AS-301
579. A Single-Dose Study to Assess the Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients with Exercise-Induced Bronchoconstriction (EIB)
#ABS-AS-302
580. A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated with Short Acting Beta₂-agonist.
LPA112186
581. A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 µg bid with placebo: a 6-week efficacy and safety study in children aged 6 to <12 years with asthma. # D589GC00001
582. A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 weeks in patients with moderate persistent asthma. #204.418
583. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol (320 mcg, once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Adult and Adolescent Subjects (12 Years of Age and Older).
BDP-AR-302
584. A randomized, dose-ranging, placebo-controlled trial to evaluate the effects of phenylephrine HCl immediate release tables on nasal congestion in subjects with seasonal allergic rhinitis
CL2010-06
585. Psychometric evaluation of a novel questionnaire designed to assess patient satisfaction with and preference of intranasal corticosteroids administered via HFA aerosol or aqueous suspension used for the treatment of allergic rhinitis
#060-301
586. A prospective, open label, Assessment of the Albuterol ProAir HFA MDI integrated dose counter # ABM-AS-307
587. A randomized, double-blind, placebo-controlled, parallel-group study comparing the bioequivalence of ciclesonide nasal spray (APOTEX, Inc.) to that of Omnaris nasal spray (Sepracor, Inc.) in the treatment of seasonal allergic rhinitis
CICE-NASU-05SB03-CE
588. A randomized, placebo- controlled, parallel group study to assess the efficacy, safety, and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma
CQAW039A2201
589. A randomized, placebo-controlled trial to evaluate the effects of Phenylephrine HCl 30 mg Extended Release Tablets on nasal congestion in subjects with allergic rhinitis
CL2011-06

590. A randomized, double-blind, placebo-controlled, parallel-group, multi-center study to assess the efficacy and safety of BDP HFA Nasal Aerosol in pediatric subjects (6 to 11 years of age) with seasonal allergic rhinitis (SAR)
BDP-AR-305
591. A 12-week, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy, safety, and patient use (User Study) of Symbicort® (budesonide/formoterol) Breath Actuated Metered Dose Inhaler (BA MDI) 2x160/4.5 µg twice daily compared with Symbicort (budesonide/formoterol) AC (actuation counter) pMDI® 2x160/4.5 µg twice daily and budesonide AC pMDI 2 x 160 µg twice daily in adult and adolescent asthmatics
D5890C00003
592. An open label randomized two period two-way crossover study to evaluate efficacy, patient preference and satisfaction with Ciclesonide Nasal aerosol versus Mometasone Furoate Aqueous Suspension used for the treatment of allergic rhinitis
#060-302
593. Double-blind, double-masked, randomized, placebo-controlled, cross-over study of the bronchoprotective effect of generic levalbuterol tartrate HFA and Xopenex HFA® (levalbuterol tartrate) metered-dose inhaler (MDI) formulations against methacholine-induced bronchoconstriction in asthmatic subjects
C-2010-05
594. A 12-month, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations and change in lung function in patients (12-75 years of age) with eosinophilic asthma
C3072/3082
595. A 12-Week randomized, double-blind, placebo-controlled, parallel group, safety and efficacy study of ciclesonide nasal aerosol in subjects 6-11 years with perennial allergic rhinitis
SEP 060-306
596. A 12-week dose-ranging study to evaluate the efficacy and safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) administered twice daily compared with placebo in adolescent and adult subjects with persistent asthma uncontrolled on nonsteroidal therapy
#FpS-AS-201
597. A multicenter, consumer product evaluation of a single dose of Phenylephrine HCl 30mg Extended Release Tablets (Sinus Comfort)
#CL2012-03
598. A randomized, placebo-controlled, dose-ranging, multi-centre trial of QAW039 (1- 450 mg p.o.) to investigate the effect on FEV₁ and ACQ in patients with moderate-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy #CQAW039A2206
599. A 2-week randomized, double blind, placebo controlled, parallel group, safety and efficacy study of Ciclesonide Nasal Aerosol in subjects 6 to 11 years with seasonal allergic rhinitis
#060-305
600. Non-invasive neurostimulation of the Vagus Nerve for the relief of acute bronchoconstriction due to asthma #BC-US-06
601. Evaluation of hypoallergenicity of an amino acid-based infant formula #09.55 PED
602. A phase 2, multicenter, parallel-group, randomized, double-blind, placebo- and active comparator-controlled, combination study of S 555739 and Cetirizine HCl in adult patients with seasonal allergic rhinitis
#1210D1526

603. A double-blind, placebo-controlled, four-way crossover study to compare the safety and efficacy of ONO-6950 20 mg and 200 mg QD versus placebo and Montelukast (Singulair) in asthmatic patients who exercise-induced bronchoconstriction
#ONO6959POU004
604. ACQ, AQLQ, RQLQ Equivalence Study #1788A
605. Asthma Control Diary (ACD) Equivalence Study #1643A
606. A phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of inhaled R940343 in patients with mild to moderate allergic asthma
#C-940343099
607. A multi-center, randomized, double-blind, vehicle-controlled, cross-over evaluation of the effects of KD1157 nasal spray on nasal challenge with allergen #KD1157-AR02
608. A multi-center 52-week study to assess the safety of Albuterol *Spiromax*® in subjects with asthma #ABS-AS-307
609. A randomized, placebo-controlled, Phase IIb dose-finding study of CYT003-QbG10, a TLR9-agonist, in patients with moderate to severe allergic asthma not sufficiently controlled on current standard therapy (GINA steps 3+4)
#CYT003-QbG10.
610. A Phase III, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Uncontrolled Asthma who are on Inhaled Corticosteroids and a Second Controller Medication.
#GB28688
611. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma.
#BDB-AS-301
612. A Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) or Metered Dose Inhaler (MDI) in Pediatric Patients 5 Through 11 Years of Age with Persistent Asthma.
#BDB-AS-302
613. A Randomized, Double Blind, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate (80 and 160 mcg/day) Delivered via Breath Actuated Inhaler (BAI) in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma.
#BDB-AS-304
614. A Randomized, Double Blind, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate (80 and 160 mcg/day) Delivered via Breath Actuated Inhaler (BAI) in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma.
#BDB-AS-304
615. Oral Desensitization to Peanut in Peanut Allergic Children and Adults using Characterized Peanut Allergen (CPNA) Oral Immunotherapy (OIT)
#ARC001

616. Double-Blind, Randomized, Crossover Allergy Study of an Extensively Hydrolyzed Casein formula (NPS-G19A) Followed by a 16 Week Double Blind Feeding Period to Assess Growth, Safety and the Development of Tolerance to Cow's Milk Protein.
#PRG-VA-14-001
617. A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older with Persistent Asthma.
#FSS-AS-305
618. Oral Desensitization to Peanut in Peanut-Allergic Children and Adults using Characterized Peanut Allergen (CPNA) Oral Immunotherapy (OIT) Safety Follow-On Study.
#ARC002
619. A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects with a History of House Dust Mite-Induced Rhinoconjunctivitis
#TH005
620. A Randomized, Double-Blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to Advair® Diskus® Administered via Oral Inhalation in Adult Asthma Patients.
#MGR001-3001
621. Exploratory Evaluation of Nasal Strips in Children.
#RH02599
622. Identification and Description of Severe Asthma Patients in a Cross-sectional Study--the IDEAL Study.
#01

PRESENTATIONS:

1. Mastocytosis Syndrome: Case Report and Pharmacologic Control of Mediator Effects. American College of Allergists, San Francisco, California, April, 1984.
2. Occupational Allergy to Honeybee Whole Body Dust in Honey Processing Plant. American Academy of Allergy and Immunology, New York City, New York, March, 1985.
3. Allergy Should Not Be Considered Science Fiction, Just Science. Workshop presentation for Pediatric Days, Mayo Clinic and Mayo Medical School, Rochester, Minnesota, April, 1985.
4. Approach to the Pediatric Patient with Urticaria. Pediatric Grand Rounds, Children's Hospital and Health Center, San Diego, California, November, 1986.
5. Varicella Infection in the Immunocompromised Host. Pediatric Immunology and Allergy Division, University of California, San Diego, California, July, 1987.
6. Recognition and Management of the Student with Allergies/Asthma at School. California School Nurses Association, San Diego, California, January, 1988.
7. Common Problems in Pediatric Allergy and Asthma. Pediatric Grand Rounds, Children's Hospital and Health Center, San Diego, California, August, 1988.
8. Diagnosis and Treatment of Allergic Respiratory Diseases. Palomar Hospital, Escondido, California, January, 1989.
9. Allergy and Asthma Treatment in the 1980's and Beyond. San Diego Retail Pharmacists Society, April 9, 1989.
10. Asthma in the Professional Athlete. Grand Rounds, Children's Hospital and Health Center, San Diego, California, November 3, 1989.
11. Evaluation and Medical Management of Pediatric Allergic Diseases and Asthma. San Diego State University School of Nursing, San Diego, California, February 21, 1990.
12. Clinical and Rhinomanometric Evaluation of Triamcinolone Acetonide Nasal Aerosol in Children with Perennial Allergic Rhinitis. American Academy of Allergy and Immunology, Baltimore, Maryland, March 21, 1990.
13. New Advances in Asthma Therapy. Pediatric CME Conference, Grossmont Hospital, San Diego, California, March 24, 1990.
14. Non-pharmacologic Approaches to Allergic Disease. Current Concepts in Pediatric Allergy and Otolaryngology. American Academy of Pediatrics, CME Program, June 30, 1990.
15. Food Allergy: How Common, How Important? Current Concepts in Pediatric Allergy and Otolaryngology. American Academy of Pediatrics, CME Program, June 30, 1990.
16. Approaching Asthma From All Angles. Children's Hospital and Health Center Asthma Education Program Development, May 1990.
17. Beta₂ Agonists. Pediatric Resident Education Seminar, University of California, San Diego Medical Center, February 15, 1991.
18. Food Allergy: Identification, Management and Prevention. American Academy of Pediatrics Spring Session, San Diego, California, March 16, 1991.
19. Students with Allergies and Asthma. San Diego State University School of Nursing. San Diego, California, March, 1991.
20. Immunotherapy: The Oldest and Newest Anti-Inflammatory Treatment for Allergies and Asthma. Pediatric Grand Rounds, Children's Hospital and Health Center, San Diego, California, June, 1991.
21. Diagnosis and Management of Allergic Respiratory Diseases. San Diego State University School of Nursing. San Diego, California, September 12, 1991.
22. Bronchial Asthma - New Directions in Treatment. Continuing Medical Education, Student Health Services, San Diego State University, October 15, 1991.

23. Anaphylaxis and Other Reactions to Foods, Drugs, Venoms, and Exercise-Induced Asthma. Current Concepts in Pediatric Medicine, San Diego, California, February 7, 1992.
24. Asthma and Allergies in School Age Children. San Diego State University School of Nursing. San Diego, California, February 19, 1992.
25. Drug Allergy. Current Concepts in Pediatric Medicine, Children's Hospital and Health Center, San Diego, California, March 7, 1992.
26. Asthma Update: Effective Management in the School Setting. Student Well-Being, El Cajon School District, April 22, 1992.
27. Asthma: Effective Management in the School Setting. Grossmont Union High School District, April 23, 1992.
28. Asthma Update: Effective Management in the School Setting. Student Well-Being, Escondido School District, May 18, 1992.
29. Traveling with Asthma. Parents of Children with Asthma, American Lung Association, San Diego, California, June 3, 1992.
30. Status Asthmaticus: Recognition, Treatment and Prevention. Current Concepts in Pediatric Respiratory Diseases 1992, San Diego, California, June 27, 1992.
31. Overview of Allergic Disease and Outpatient Management. Childhood Asthma, Children's Hospital and Health Center, San Diego, California, July 20, 1992.
32. Exercise Induced Asthma and Respiratory Disorders in the Competitive Athlete. San Diego County Medical Society, San Diego, California, August 26, 1992.
33. Recognition and Management of Allergic Conditions and Asthma. San Diego State University School of Nursing. San Diego, California, September 17, 1992.
34. The Allergic/Asthmatic Child in the Daycare Setting. San Diego County Family Day Care Association, San Diego, California, October 3, 1992.
35. Issues of Beta Agonists. Seminar, American College of Allergy and Immunology, Chicago, November 16, 1992.
36. Asthma and Allergies in the School-Aged Child and Adolescent: Identification and Management. San Diego State University School of Nursing, San Diego, California, February, 1993.
37. Asthma, Allergies and the Athlete. El Cajon School District Coaches and Physical Education Teachers, Continuing Medical Education, El Cajon, California, February, 1993.
38. New Directions in Asthma Management. Pediatrics Update 1993, Continuing Medical Education, San Diego, California, February 15, 1993.
39. Food Allergy: Fact vs. Fiction. Pediatrics Update 1993, Continuing Medical Education, San Diego, California, February 15, 1993.
40. Pulmonary Function Testing in Pediatric Respiratory Disease. Pediatrics Update 1993, Continuing Medical Education, San Diego, California, February 15, 1993.
41. Pathophysiology and Medical Management of Allergies and Asthma. San Diego State University School of Nursing, San Diego, California, March, 1993.
42. Basic Non-Pharmacologic Approaches to Allergic Disease. Current Concepts in Pediatric Allergy & Otolaryngology 1993, Children's Hospital and Health Center, Continuing Medical Education, San Diego, California, June 12, 1993.
43. Allergies and Asthma in the School Setting. Current Concepts in Pediatric Allergy & Otolaryngology 1993, Children's Hospital and Health Center, Continuing Medical Education, San Diego, California, June 12, 1993.
44. Issues of Stinging Insect Allergy. Grand Rounds, Children's Hospital and Health Center, San Diego, California, July 30, 1993.
45. Food Allergy: Fact vs. Fiction. San Diego State University Student Health Services, Continuing Medical Education, San Diego, California, September 9, 1993.

46. Pediatric Allergy and Asthma. San Diego State University School of Nursing, San Diego, California, September 23, 1993.
47. Allergy and Asthma Management in the School-Aged Child. San Diego State University School of Nursing, San Diego, California, February 15, 1994.
48. Pediatric Allergy and Asthma. San Diego State University School of Nursing, San Diego, California, February 24, 1994.
49. The Pathophysiology and Treatment of Asthma. ACAI Regional Allied Health Professionals Course, San Diego, California, June 4, 1994.
50. Use of Inhalational Medications. ACAI Regional Allied Health Professionals Course, San Diego, California, June 4, 1994.
51. Summer Allergy - Sneeze, Wheeze and Killer Bees. Pediatric Grand Rounds, Children's Hospital and Health Center, July 8, 1994.
52. Hospital and Health Center, July 8, 1994.
53. Medical Management of Allergies and Asthma. San Diego State University School of Nursing, San Diego, California, February 22, 1995.
54. New Developments in Asthma Management: the Pharmacists' Role. Rhone-Poulenc Rorer Pharmaceuticals, San Diego, California, March 29, 1995.
55. Pediatric Allergy. Scripps Clinic Allergy Conference, La Jolla, California, September 19, 1995.
56. Management of Allergic Rhinitis. Mercy Hospital Grand Rounds, San Diego, California, September 26, 1995.
57. Treatment of Chronic Asthma. American Lung Association Pediatric Asthma Education Program, San Diego, California, November 18, 1995.
58. Asthma Management. San Diego State University School of Nursing, San Diego, California, February 13, 1996.
59. Asthma Management for Quality of Life: The Patient - Healthcare Provider Alliance. California Coalition of Nurse Practitioners, San Diego, California, March 15, 1996.
60. Long-Acting Beta Agonists. Eastern Allergy Conference, Bermuda, April 18, 1996.
61. The Stuffy Nose: How to Cope. Current Concepts in Pediatric Allergy and Otolaryngology, Coronado, California, July 5, 1996.
62. Sneezes, Sniffles, and Salutes - Stifling Allergic Rhinitis. Speaker and Session Moderator, Current Concepts in Pediatric Allergy and Otolaryngology, Coronado, California, July 6, 1996.
63. Allergy and Asthma in Children. School of Nursing, San Diego State University, San Diego, California, March 18, 1997.
64. Asthma Management. School of Nursing, San Diego State University, San Diego, California, April 22, 1997.
65. Testimony from clinician investigator perspective to FDA Pulmonary and Allergy Advisory Panel regarding policy making for transition to CFC-free metered-dose inhalers for allergy and asthma treatment. Advanced Notice of Proposed Rule making, hearing in Washington, DC, May 9, 1997.
66. Demographic Population in Clinical Research Trials; Relevance of the NDA to the Real World. Workshop, American Academy of Allergy Asthma and Immunology. Washington, DC, March 1998.
67. Pharmacotherapy for Allergic Diseases and Asthma: Literature Review. American College of Allergy, Asthma and Immunology Annual Meeting, 1998.
68. It Itches! Measures to Smooth the Bumps (Evaluation and Management of Urticaria and Angioedema. Primary Medicine Today, Long Beach, California, April 1999.
69. Outpatient Management of Asthma: Keeping Kids in School. Current Concepts in Pediatric Allergy and Otolaryngology, Children's Hospital and Health Center, San Diego, California, July, 1999.

70. Recognizing the Unusual: Hoofbeats That Are Zebras. Current Concepts in Pediatric Allergy and Otolaryngology, Children's Hospital and Health Center, San Diego, California, July, 1999.
71. Pharmacotherapy for Allergic Diseases and Asthma: Literature Review. American College of Allergy, Asthma and Immunology Annual Meeting, Chicago, Illinois, November, 1999.
72. Pharmacologic Management of Allergic Illness. American College of Allergy Asthma and Immunology Annual Meeting, Seattle, Washington, November 2000.
73. Clinical Perspectives on Beta-Agonist Therapy in Special Populations. Speaker and Session Moderator, American Academy of Allergy Asthma and Immunology Annual Meeting. New Orleans, March 2001.
74. Scope and Impact of Allergic Rhinitis. American Academy of Pediatrics Symposium, San Francisco, California, October 2001.
75. Pharmacologic Management of Allergic Diseases and Asthma. American College of Allergy Asthma and Immunology Annual Meeting, Orlando, Florida, November 2001.
76. Dinner Symposium 5803: Clinical Perspectives on Beta-Agonist Therapy in Special Populations. AAAAI 57th Annual Meeting Program Evaluation, 2001.
77. Asthma and Allergic Diseases in Women. Symposium Moderator, American Academy of Allergy Asthma and Immunology, New York City, New York, March 2002.
78. Medical Issues and Legal Consequences of Allergic Rhinitis Treatment. Primed Symposium, Long Beach, California, April 2002.
79. Pharmacotherapy for Allergic Diseases. American College of Allergy Asthma and Immunology Annual Meeting, San Antonio, Texas, November 15, 2002.
80. Guidelines for Treatment of Pediatric Asthma. Pediatric Department CME Conference, Scripps Memorial Hospital, Department of Pediatrics, San Diego, California, February 12, 2003.
81. Allergist and Pulmonologist Prescribing of Inhaled Corticosteroids for Pregnant and Nonpregnant Women with Asthma. American Academy of Allergy Asthma and Immunology 60th Annual Meeting, Denver Colorado, March 10, 2003.
82. Update on Asthma and Allergic Diseases in Women; Moderator. American Academy of Allergy Asthma and Immunology 60th Annual Meeting, Denver Colorado, March 10, 2003.
83. Insights Into the Management of Airways Diseases in Special Populations: Considerations in Women of Childbearing Age. American Academy of Allergy Asthma and Immunology 60th Annual Meeting, Denver Colorado, March 11, 2003.
84. Issues in Women of Childbearing Age. XIII Latin American Congress of Allergy, Asthma and Immunology, Cancún, Quintana Roo, Mexico, June 24, 2003.
85. Issues of Asthma in Women of Childbearing Age. American College of Allergy, Asthma and Immunology Annual Meeting, New Orleans, LA, November 7, 2003.
86. Developing the CRC (Certified Research Coordinator). American Academy of Allergy, Asthma and Immunology 61st Annual Meeting, San Antonio, Texas, March 18, 2005.
87. Pharmacotherapy for Asthma and Rhinitis in Pregnancy and Women of Childbearing Age. American Academy of Allergy, Asthma and Immunology 61st Annual Meeting, San Antonio, Texas, March 21, 2005.
88. Pediatric Asthma Management: The Unmet Need. American Academy of Pediatrics, National Conference and Exhibition, Washington, DC, October 8, 2005.
89. Good Clinical Practice: CRN. 2006 "Value Added" Program, Irving, TX, April 29, 2006.
90. Managing Asthma. Women's Health Congress, San Francisco, Ca, November 11, 2006.
91. Unique Observations of Asthma in Women. American Academy of Allergy, Asthma and Immunology Annual Meeting, San Diego, California, February 27, 2007.
92. Optimizing Patient Management: Effectively Monitoring and Treating Special Populations. American College of Allergy, Asthma and Immunology Annual Meeting, Dallas, Texas, November 9, 2007.

93. Is Asthma Different in Women? American Academy of Allergy, Asthma and Immunology, Philadelphia, Pennsylvania, Mar. 17, 2008.
94. Effect of Hormones on Allergic Diseases. American Academy of Allergy, Asthma and Immunology Annual Meeting, Washington DC, March 14, 2009.
95. Asthma Therapy; Moderator. American Academy of Allergy, Asthma and Immunology Annual Meeting, Washington DC, March 14, 2009.
96. Diagnosis and Management of Asthma in Children; Moderator. American Academy of Allergy, Asthma and Immunology Annual Meeting, Washington DC, March 14, 2009.
97. Why and How does Exercise Cause Asthma Symptoms: Lessons Learned from the 2008 Olympics. Moderator. American Academy of Allergy, Asthma and Immunology Annual Meeting, Washington DC, March 14, 2009.
98. A Comprehensive Survey of Healthcare Professionals and Asthma Patients Offering Insight on Current Treatment Gaps and Emerging Device Options (C.H.O.I.C.E.) Study: Patient Perception of Symptom Control. (abstr) American Academy of Allergy Asthma & Immunology Annual Meeting, New Orleans, LA, February 27, 2010.
99. Management of Asthma and Allergy During Pregnancy. American Academy of Allergy, Asthma and Immunology Annual Meeting, New Orleans, LA, February 28, 2010.
100. Management of Asthma and Allergy During Pregnancy. American Academy of Allergy, Asthma and Immunology Annual Meeting, San Francisco, California, March 21, 2011.
101. Managing Acute Asthma and the Child with Exercise-Induced Asthma. 2012 American College of Clinical Pharmacology Annual Meeting. San Diego, CA, September 22, 2012.
102. Special Issues in Atopy and Immunologic Diseases in Women. American College of Allergy, Asthma and Immunology. Baltimore, MD, Nov. 11, 2013.